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ABSTRACT 
Pharmacists' Expectations of a Pharmacy Network: A Baseline Evaluation 
This study was carried out to determine community pharmacists' perceived value 
of a pharmacy network prior to its implementation. A questionnaire was mailed to all 435 
community pharmacists practicing in Newfoundland and Labrador in 2002, with 217 
completed questionnaires returned (49.9% response rate). Overall, 90.3% of community 
pharmacists agreed drug utilization review would be an important function of the 
Pharmacy Network; reducing prescribing problems was found to have the strongest 
support (91.3%). For eight measures of computerized physician order entry, agreement 
ranged from 69.6% to 97.2%, with removing problems with illegible hand writing 
receiving the strongest support. Although suspected adverse reactions appears to be under 
reported, 87.6% of community pharmacists indicated they would report more if it could 
be done electronically. Considerable support was found for four measures related to 
payment for pharmaceutical services (range 82.9% to 89.4%), with a higher proportion of 
female pharmacists indicating they would expect payment. Younger pharmacists, and/or 
those working in urban areas, had a higher perceived value of a pharmacy network than 
older pharmacists and/or those working in rural areas. Differences in perceived value of 
a pharmacy network was also found between education levels and years practicing and 
gender. 
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CHAPTER I 
INTRODUCTION 
Pharmacy has evolved through phases of increasing functionality and complexity: 
compounding and dispensing, clinical pharmacy, and pharmaceutical care (Holland and 
Nimmo, 1999). fu the past, pharmacists were expected to prepare and dispense 
medications, and therefore, required skills in mixing different types of drugs. As the 
complexity of drugs grew, large drug companies assumed the role of preparing 
medications and pharmacists were left with the responsibility of dispensing medications 
(Al-Shaqha & Zairi, 2001). 
fu the late-1960s there was a shift towards pharmacists playing more of a clinical 
role (Hepler & Strand, 1990). Clinical pharmacy is defined as the provision of structured 
services by pharmacists to meet the drug-related needs of patients, physicians and nurses 
in a commitment to the optimization of drug therapy (Al-Shaqha & Zairi, 2001). Clinical 
pharmacy evolved in the hospital setting where pharmacy managers were able to 
convince hospital administrators that clinical pharmacy would reduce the incidence of 
adverse drug reactions and thus save hospital days (Penna, 1987). fu an effort to enhance 
patient care, pharmacists were made part of a care management team in the hospital 
setting. As part of this team, the pharmacist provided clinical pharmacy services to ensure 
that drug therapy was appropriate and cost-effective (Al-Shaqha & Zairi, 2001). fu 
delivering such services, the pharmacist exercised professional judgment and accepted 
the responsibility for the quality of drug-related patient care outcomes (Hepler, 1985; 
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Hepler & Strand, 1990). Clinical phannacy has resulted in safe, accurate, effective and 
efficient drug therapy. However, the clinical role of phannacists has generally been 
restricted to hospitals, nursing homes and ambulatory clinics, with minimal extension to 
community phannacies (Penna, 1987; Church, 1989; Al-Shaqha & Zairi, 2001 ). 
The phannacist's role is expanding to include the delivery of phannaceutical care, 
a model of care where the phannacist works in partnership with other health care 
professionals to maximize the health outcomes of their patients. These outcomes are: (1) 
cure of a disease, (2) elimination or reduction of a patient's symptomatology, (3) arrest or 
slowing of a disease process, or (4) prevention of a disease or symptomatology (Hepler & 
Strand, 1990). 
Phannaceutical care includes monitoring a patient's symptoms, counseling, 
resolving drug-related problems, communicating with the prescriber, and intervening 
when appropriate. This shift to phannaceutical care has presented challenges. Lack of 
training, confidence and time in the phannacist's practice have been found to be barriers 
to embracing this new model of care. Given that present day pharmacies are profit 
driven, it has been suggested that these obstacles may be difficult to overcome (Amsler, 
Murray, Tierney, Brewer, Harris, Marrero & Weinberger, 2001). 
Community phannacies continue to introduce new processes into their business 
practices to facilitate movement toward phannaceutical care (Dupclay, Rupp, Bennett & 
Jarnagin, 1999), such as the introduction of advanced technologies in support of service 
delivery. When technology was introduced into phannacies in the 1970's, it was usually 
referred to as pharmacy informatics. Pharmacy informatics included in-house 
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computerized medication profiles and inventory management systems. In recent years, 
the term Pharmacy Network has emerged, which is the linking of individual 
computerized pharmacies to a network. A Pharmacy Network is a comprehensive set of 
modules and processes that includes: establishing a relationship with the patient, creating 
a database, listing and ranking problems, providing options, and planning and monitoring 
(Felkey & Barker, 1996). A Pharmacy Network will enable pharmacists to embrace an 
even more enhanced role in the delivery of pharmaceutical care, while maintaining 
business profitability. 
Rationale 
Nine of the ten provinces currently have some form of pharmacy network. Most 
of these networks connect community retail pharmacies and provincially funded drug 
programs. The most advanced networks include the ability to provide complete drug 
profiles to pharmacists at the point of distribution. Such systems have been implemented 
in four provinces: Alberta (WellNet), Prince Edward Island (Pharmacy Network), British 
Columbia (PharmaNet) and Manitoba's Drug Programs Information Network (DPIN). 
Each of these provinces, to varying degrees, have incorporated the following functions in 
designing their Pharmacy Network: on-line real time adjudication, checks for duplication 
and double-doctoring, drug utilization reviews, checks for patient eligibility, drug 
profiles, connection to hospitals and physician offices, and electronic prescribing. 
Studies were not carried out in these provinces to determine the perceived value 
to community pharmacists before and after the implementation of a Pharmacy Network. 
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In Manitoba, a post-implementation study was carried out that measured community 
pharmacists perceived benefit of the Drug Programs Information Network approximately 
three years after implementation (Kozyrskyj, Brown & Mustard, 1998). However there 
was no comparable pre-implementation component to the study. 
The Newfoundland and Labrador Centre for Health Information (NLCHI), on 
behalf of the provincial health system and the Government of Newfoundland and 
Labrador, has been mandated to build a provincial Health Information Network (HIN). 
The first phase of the HIN, the Unique Personal Identifier/Client Registry is complete. 
The second phase of the HIN is the Newfoundland and Labrador Pharmacy Network 
(Pharmacy Network). The core function of the Pharmacy Network will be to provide 
integration between community and institutional pharmacies, the Newfoundland and 
Labrador Prescription Drug Program, hospital emergency rooms and physician offices. 
The work currently being carried out by NLCHI presents a unique opportunity to 
determine the perceived value to community pharmacists of the Pharmacy Network 
before it is implemented. This study investigated the perceptions of community 
pharmacists on such issues as the value of a complete patient profile, the usefulness of 
drug utilization reviews, and electronic prescribing and payment for pharmaceutical care. 
The results of this study provides benchmarks for future comparative studies that measure 
perceived value post-implementation of the Pharmacy Network. Other jurisdictions will 
be able to use the results of this study as pre-implementation benchmarks for future 
pharmacy networks. 
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Objectives 
The objectives of this study were: 
1) To measure the perceived value to community pharmacists of specific role 
enhancements (i.e., pharmaceutical care) as a result of implementing the Pharmacy 
Network. 
2) To measure the perceived impact that changes in business practices will have on 
community pharmacists as a result of the Pharmacy Network. 
3) To identify key functions of the Pharmacy Network, and to determine the perceived 
benefit to community pharmacists ofthese functions. 
Literature Review 
A review of relevant literature concerning (1) the evolution of community pharmacies, 
(2) functions of Pharmacy Networks, (3) existing Pharmacy Networks in Canada, (4) 
proposed functions of the Newfoundland and Labrador Pharmacy Network, (5) perceived 
value of a Pharmacy Network to community pharmacists pre-implementation, and (6) 
payment for pharmaceutical care is presented below. 
Evolution of Community Pharmacies 
For hundreds of years, the primary role of pharmacists was to prepare and 
dispense medications (Al-Shaqha & Zairi, 2001). In the mid-1960's, there was a shift in 
the role of pharmacists that led to them taking on more clinical involvement in the care of 
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their patients (Hepler & Strand, 1990). Clinical pharmacy evolved based on the 
philosophy that pharmacists needed to expand their functions to include other health care 
professionals in the process of dispensing medications (Penna, 1987). During this time, 
pharmacists began to incorporate new functions, which was then followed by a period of 
enhancement to these functions based on their practical applications (Hepler & Strand, 
1990). The era of clinical care moved the pharmacist role from one of only providing a 
dispensing service to one where they played an active part in determining the most 
appropriate treatment for patients. From a conceptual perspective, clinical pharmacy is 
the combination of knowledge, skills and ethics that allows for optimal safety in the 
distribution and use of medications (Brodie, 1986, as cited in Penna, 1987). 
The role of today's pharmacist is now shifting from clinical care to 
pharmaceutical care, a system of medication prescribing shared by pharmacists and other 
health care professionals. Pharmaceutical care incorporates both traditional dispensing 
roles with the more established functions of clinical care; pharmacists share this 
responsibility with other health professionals in providing optimum patient care (Babb & 
Babb, 2003). Hepler & Strand (1990) predict the role of the pharmacist, in partnership 
with other health care professionals, will be enhanced to a point where pharmacists will 
design, implement and monitor therapeutic plans for their patients. 
There are three major components to pharmaceutical care: (1) identifying 
potential and actual drug-related problems, (2) resolving actual drug-related problems 
and (3) preventing potential drug-related problems (Al-Shaqha & Zairi, 2001 ). A study 
carried out by Amsler et al., (2001) found that pharmacists believed pharmaceutical care 
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included "educating patients on medicine and disease states" and "telling patients why 
they take a medicine, the effects, the side effects, and the outcomes, and checking 
medication compliance" (p. 851 ). 
The acceptance of pharmaceutical care as the new way for pharmacists to do 
business has not been without its challenges. The actual layout of most pharmacies does 
not allow for one-on-one consultations with patients (Amsler, et al., 2001), and even 
though pharmacists today spend less time dispensing medications than in the past, they 
still have little time to devote to patient care activities (Schommer, Petersen, Doucette, 
Gaither & Mott, 2002). The minimal amount of time pharmacists currently spend on 
pharmaceutical care is also related to the fact that they are paid for dispensing 
medications, not for pharmaceutical care services (Bennett, Blank, Bopp, James & 
Osterhaus, 2000). While pharmacists believe in the value of such services, and feel they 
are capable of providing them, they also expect to be reimbursed for these services 
(Miller & Ortmeier, 1995; Kozyrskyi, et al., 1998; Christensen, Neil, Fassett, Smith, 
Holmes & Stergachis, 2000). The resistance by other health care professionals to 
pharmacists taking a more active role in patient care has also been identified as a barrier 
to pharmaceutical care (Amsler, et al., 2001; Hepler & Strand, 1990). Even when 
cooperation exists between pharmacists and other providers, the lack of technological 
communication between institutional and community based information systems, or 
services, makes it difficult to share patient information. 
In spite of these barriers, the adoption of the pharmaceutical care model by 
pharmacists must be realized if the pharmacy profession is to survive. Advances in 
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technology will be accompanied by more mail order pharmacies and automated 
dispensing systems, which will make the traditional dispensing role of a pharmacist 
obsolete (Hepler, 1988). Pharmacists can play an important role in reducing patient 
morbidity and mortality through pharmaceutical care, and patients are willing to pay 
extra for this service (Suh, 2000; Larson, 2000). In the long term, pharmacists can expect 
to make greater profits from pharmaceutical care than from simply dispensing 
medications (Bennett, et al., 2000), although the transition period may be expensive 
(Norwood, Sleath, Caiola & Lien, 1998). 
Functions of Pharmacy Networks 
In any health care system there are four distinct levels of technological 
architecture: (1) the foundation layer formed by a transaction-processing system, (2) a 
management information system, (3) decision support and (4) advanced informatics 
systems (Felkey, 1997). A transaction-processing system is one which captures an event 
(transaction) and from this an output is produced (process). An example of a transaction-
process would be the prescribing of a drug by a physician (transaction) and the filling of 
that prescription by a pharmacist (process). A management information system generates 
reports that provide managers with information about what is occurring in the 
transaction-processing system. An example of this system would be a drug inventory 
management system for a pharmacy. The decision support layer provides real time access 
to information used in deciding appropriate patient care. For example, immediate access 
to clinical practice guidelines prior to filling a prescription is a common decision support 
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tool used in pharmacies. The final level would include advanced informatics applications 
such as artificial intelligence systems. Artificial intelligence is a recent branch of science 
which simulates the functions of the human brain to solve various problems using 
computers. A study by Ald, Sobh, Enab & Tattersall (2001) concluded artificial 
intelligence provided enhanced patient care in the prescription and monitoring of 
hemodialysis therapy. 
Existing Pharmacy Networks in Canada 
Information systems developed to capture data related to prescription medications 
are variable in function across Canada. In the past these systems were developed to 
process claims for government-funded drug programs. Technological advances in the last 
10 years now allow for more enhanced functionality of medication systems (Pharmacy 
Networks). These systems provide an opportunity to capture real time medication data, 
which can lead to health, economic and financial benefits for both governments and 
individual patients (Benefits Driven Business Case, NLCHI, 1998). 
Nine of the ten provinces currently provide adjudication functions for government 
drug programs. However four provinces, Manitoba, British Columbia, Alberta and Prince 
Edward Island have implemented (or are planning to implement) systems with more 
comprehensive functional capability. The main enhancement found in these systems is 
the ability to provide real time patient drug profiles at the time the prescription is filled by 
the pharmacist (Pharmacy Network Briefing Note, NLCHI, 2002). 
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The four provinces that have in place, or are in the process of implementing, 
comprehensive Pharmacy Networks have developed similar functions. A comparative 
listing of these functions is provided in Table 1, followed by a brief description of each of 
these province's networks. 
Table 1 
Functions of Selected Provincial Pharmacy Networks 
Alberta British Manitoba PEI Function Columbia (2002) (1995) (1994) (1999) 
On-line real time adjudication and transmission ./ ./ ./ ./ 
Checks for duplication ./ ./ ./ ./ 
Checks for double-doctoring ./ ./ ./ ./ 
Provides full retrospective drug use 
evaluation/review on patient profile 
./ ./ ./ ./ 
Tracks patient's deductible on co-pay ./ ./ ./ ./ 
Patient eligibility checked ./ ./ ./ ./ 
Immediately identifies what is and is not a benefit ./ ./ ./ ./ 
Pharmacare Status ./ ./ ./ ./ 
Drug Profiles ./ ./ ./ ./ 
Drug Profiles history on each patient ./ ./ ./ ./ 
Note: not 
Records Rx dispensed for all or select group of Will record All mandatory for Will report all 
all prescriptions aboriginals, patients prescriptions are recorded but most prescriptions 
recorded. 
Ability to record non-dispensing events ./ 
Connected with hospitals ./ ./ 
Connected with physician offices/desk top 
./ 
prescribing 
Currently in a Five year In the Other Notes 6 month pilot plan. development 
stage. stage. 
Pharmacy Scopmg ProJect Bnefing Note, 2002 (NLCHI) 
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Manitoba 
In 1994, the province of Manitoba implemented the Drug Programs Information 
Network (DPIN). The DPIN system was the first system in Canada that connected all 
community pharmacies. There are currently no linkages of community physicians to 
hospitals, although these connections are part of Manitoba's five-year business plan for 
the DPIN. The DPIN was originally developed to provide complete prescription profiles 
to pharmacists at the time of dispensing, as well as enhanced drug utilization reviews. 
The functions of the DPIN system are similar to other provinces with Pharmacy 
Networks (see Table 1), although in Manitoba it is not mandatory for pharmacists to 
record prescriptions filled by Registered Indians (Kozyrskyj, et al., 1998). 
British Columbia 
The British Columbia PharmaNet initiative was implemented in 1995 in an 
attempt to contain escalating costs to the government drug program, and to improve the 
health of the population through the provision of drug therapy decision tools. The 
network allows for the exchange of medication information between pharmacists and 
hospital emergency rooms, however there are no linkages to community physicians. 
An additional function of the PharmaNet system is the Pharmacare Trial 
Prescription Program. This module was developed to reduce expenditures for patients 
who are put on a new medication and for some reason must discontinue its use. A patient 
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is given only a portion of the new drug, and their health care provider then monitors their 
progress. If for some reason the drug must be discontinued, the full prescription has not 
been wasted. 
Alberta 
The Pharmaceutical Information Network (PIN) is being developed in Alberta as 
part of the Alberta Wellnet initiative. The objective of the PIN project is to provide 
health care professionals with the information necessary to make optimal decisions on 
drug therapy. The network will not only provide adjudication functions for Alberta's 
government drug plan, it will also connect community pharmacists, physicians and 
hospitals to allow for the exchange of patient information. This will allow a physician to 
monitor a patient's current, as well as, historical drug profile, create/modify prescriptions 
through Computerized Physician Order Entry (CPOE), and access decision support tools 
to assist in drug therapy decisions. The PIN project in Alberta was approved for 
implementation based on the estimated $69 million the province would save annually as a 
result of a reduction in adverse drug events (Pharmaceutical Information Network -
Medication Information Strategy (White Paper), Western Health Information 
Collaborative, April2002). 
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Prince Edward Island 
Prince Edward Island is the latest province to begin developing a Pharmacy 
Network. At present this system is still in the implementation stage and much of the 
system development documentation is classified as proprietary. It is known that in 1997 
the province implemented a Pharmaceutical Informatics Project (PhiP) system, which 
provided province-wide networking for the submission of pharmacists' claims to the 
government drug program. In 1999, this system was enhanced to allow fee-for-service 
physicians to submit medical claims to government for payment. Recently, the Province 
has started a process towards developing a Pharmacy Network that would enhance the 
role of the pharmacist by providing comprehensive functionality. It is not unreasonable 
to assume this system would include similar functions found in the three provinces with 
established Pharmacy Networks. 
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Proposed Functions ofthe Newfoundland and Labrador Pharmacy Network 
Although provinces vary in the comprehensiveness of functions of their Pharmacy 
Networks, the main functions include real time adjudication of claims, checks for 
duplication and double-doctoring, retrospective drug reviews, drug profiles, and 
electronic interfaces between community pharmacies, hospitals and physicians 
(Pharmacy Network Briefing Note, NLCHI, 2002). A detailed summary of the results 
from the scoping exercise carried out by the Newfoundland and Labrador Pharmacy 
Network Project Team is provided in Appendix "A". In Newfoundland and Labrador it 
has been proposed that the Pharmacy Network would support a) drug utilization reviews, 
b) computerized physician order entry, c) post-market surveillance (Adverse Drug 
Reaction reporting) and d) complete patient medication profiles. (Stakeholder 
Consultation Presentation, NLCHI, 2002). Each of these four functions are discussed 
below. 
a) Drug Utilization Review 
Drug interactions are well known to cause adverse drug events, but most 
information captured on such events has occurred in hospitals (Cited in Halkin, Katzir, 
Kurman, Jan & Mlakin, 2001). Originally, DURs were designed to contain the costs of 
drug therapy for patients covered by Medicaid in the United States and were performed 
retrospectively. Most drug utilization reviews (DUR) currently in use today alert the 
pharmacist in real time that there may be a problem with dispensing a prescription. In 
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recent years DURs have expanded to identify potential prescribing problems. Generally, 
DUR alerts identify the possibility of therapeutic duplication, drug interactions, low/high 
dose, drug over-use/under-use and drug-pregnancy conflicts (Armstong & Denemark, 
1998). A meta-analysis of 39 prospective studies estimated the incidence of serious 
adverse drug reactions (ADRs) requiring hospital admissions was 4.7%, while a further 
2.5% of ADRs occurred for patients already admitted (Lazarou, Pomeranz & Corey, 
1998). A more recent study concluded that 5% of all hospital admissions were the result 
of ADRs (Ring & Brockow, 2002). In spite ofthe established benefits of real time access 
to DURs, community pharmacists have been slow to accept this function, given that most 
pharmacies do not have the necessary technology in place that would support electronic 
communication with ambulatory and acute care information systems (Wertheimer & 
Kralewski, 1993). If such network interfaces were available to community pharmacies, 
pharmacists would be able to make more informed decisions, resulting in better clinical 
decisions (Warholak-Juarez, Rupp, Salazar & Foster, 2000). 
b) Computerized Physician Order Entry 
Medication errors occur frequently and have both financial and clinical 
consequences (Kaushal & Bates, 2002). Unfortunately, there has been limited research on 
the value of computerized support tools in reducing medication errors in the primary care 
setting, as the setting for most such studies are hospitals (Hunt, Haynes, Hanna & Smith 
K, 1996). A recent study of primary care physicians in Quebec found 18% less 
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potentially inappropriate prescriptions dispensed per 1,000 patient visits in the physician 
group using computerized decision-making support (CDS) tools, than the physician 
group not using CDS (Tamblyn, Huang, Perreault, Jacques, Roy, Hanley, McLeod and 
Laprise, 2003). 
It has been estimated that as much as 30% of all hospital admissions resulting 
from adverse drug reactions are preventable (Bates, Cullen, Laird, Pertersen, Small, 
Servi, Laffel, Sweitzer, Shea, Hallisey, et al., 1995). The pediatric population is at 
increased risk of medication error, given that most pediatric dosing is weight based, and 
therefore can benefit greatly from electronic prescribing (Fortescue, Kaushal, Landrigan, 
McKenna, Clapp, Federico, Goldman & Bates, 2003). The fact that errors occur in the 
dispensing of medications cannot be blamed solely on the healthcare provider. Most often 
it is the result of the provider being part of a poorly designed communication network 
(Leape, Bates, Cullen, Cooper, Demonaco, Gallivan, Hallisey, Ives, Laird, Laffel, et al., 
1995; Kuperman & Gibson, 2003). There is considerable evidence that there are major 
problems with the order entry stage of prescribing medications. Computerized Physician 
Order Entry (CPOE) is one strategy that has gained wide acceptance towards improving 
this process. 
CPOE, also referred to as electronic prescribing, can enhance patient safety 
during the dispensing process in many ways. Benefits of a CPOE include: default doses 
for "normal'' conditions, removing problems inherent with illegible handwriting, 
checking dose-ceilings and patient allergy information, screening for drug-drug 
interactions, reviewing medication history, providing real time information on dose 
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algorithms, medication appropriateness, and providing less expensive alternatives 
(Briceland, 2001). 
Medication errors resulting from handwritten prescriptions has been widely 
studied. (Peterson, Wu & Bergin, 1999; Ferren, 2002). A recent study by Bizvoi, 
Beckley, McDade, Adams, Lowe, Zechnich & Hedges (2002), found that prescriptions 
filled through CPOE were three times less likely to contain errors and five times less 
likely to require pharmacist intervention than handwritten prescriptions. A hospital based 
study by Lee, Teich, Spurr & Bates (1996) found nurses valued the clear, unambiguous, 
typed medication orders provided through CPOE. The value of CPOE in addressing 
illegible handwriting has now branched out to other areas in the health sector. A study by 
Khorasani (2001) concluded that if CPOE were to be implemented in radiology 
departments, the accuracy of information would improve, which would assist the 
radiologist in making a more informed diagnosis. 
CPOE can provide valuable information on what is considered the normal dosage 
(i.e., strength), route (e.g., by mouth), frequency (e.g., twice a day) and quantity of 
specific medications. Other instructions for proper usage, such as taking medication with 
food, can also be provided. In a study of cardiovascular patients by Lapointe & Jollis 
(2003), it was estimated that 35.3% of all pharmacist interventions were the result of 
inaccurate medication dosage, while a study of pediatric patients by Fortescue, et al., 
(2003) found 28% of medication errors were errors in dosing, 18% route and 9% 
frequency. An adult based hospital study by Lustig (2000) found that 27.5% of 
medication errors were errors in dosing, 11.2% errors in route and 11.2% errors in 
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frequency. Bates, Teich, Lee, Seger, Kuperman, Ma'Luf, Boyle & Leape (1999) found 
the most frequent error typse were dosage errors, followed by frequency and route errors. 
While a CPOE system can provide guidelines, offer alternatives and recommend 
appropriate doses, route and frequencies, there are also individual characteristics that 
need to be taken into consideration. Dose algorithms, based primarily on laboratory tests, 
can suggest appropriate dosing for specific drugs by checking laboratory tests and 
individual patient characteristics such as age, weight and sex (Bates, Leape, Cullen, 
Laird, Petersen, Teich, Burdick, Hickey, Kleefield, Shea, Vliet & Seger, 1998). Providing 
real time information on dose algorithms is particularly important for pediatric (Kaushal, 
Bates, Landrigan, McKenna, Clapp, Federico & Goldmann, 2001) and geriatric patients 
(Venot, 1999). 
Medication errors resulting from known allergies, while among the rarest of errors 
have the potential to cause the most harm (Bates et al., 1999). Evans, Pestotnik, Classen, 
Base & Burke (1992) found that computer-assisted decision support tools improved the 
quality of antibiotic prescribing, partly by decreasing the number of allergic reactions. In 
the study by Bates, et al., (1999), an 80% reduction in known allergy errors was found 
after the implementation of CPOE, while a adult study of a 650 bed community hospital 
concluded that a computer alert system could reduce all ADE injuries by as much as 64 
per 1,000 patient admissions (Raschke, Gollihare, Winderlich, Guidry, Leibowitz, Peirce, 
Lemelson, Heisler and Susong, 1998). CPOE is a powerful tool which can solve many 
problems associated with medication use through providing information on drug 
selection, prescription checks and information on drugs and prescriptions (Venot, 1999). 
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In 1999 the Institute of Medicine generated considerable public interest in the problem of 
medical errors when it released its report To Err is Human (1999). The report called for 
more extensive use of available technologies to improve medication safety. 
In spite of the recent attention to enhanced patient safety, the widespread 
implementation of CPOE has yet to occur. Recent studies of US hospitals found that only 
4.3%-15.0% of hospitals have implemented CPOE (Kaushal, Shojania & Bates, 2003), 
while in Canada, only Alberta has connected physician offices with community 
pharmacies for the purpose of electronic prescribing (Pharmacy Seeping Project Briefing 
Note, NLCHI, 2002). The reasons for the slow pace at which CPOE has been 
implemented are varied. A study by Birkmeyer, Lee, Bates & Eickmeyer (2002) 
compared the cost of implementing CPOE to the potential savings through improved 
patient safety. The study concluded that implementing CPOE would be very costly for 
many organizations, and while potential savings may offset the implementation cost, they 
were difficult to quantify. Other barriers to the implementation of CPOE include the 
reluctance of physicians to change current practices (Foster & Antonelli, 2002), the lack 
of communication among physicians, nurses and pharmacists (Fortescue, et al., 2003), 
and the fact that earlier CPOE systems where not user-friendly, a legacy which continues 
to retard the use of today's more advanced (and user-friendly) CPOE systems (Parker, 
2003). 
More recent problems associated with CPOE are that as they become more 
advanced, the more critical it becomes to monitor performance. Abookire, Teich, 
Sandige, Paterno, Martin, Kuperman & Bates (2000) found that physicians regularly 
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allowed medication-allergy pairs, while a study of medical students and residents by 
Oppenheim, Vidal, Velasco, Boyer, Cooper, Hayes & Frayer (2002) found that trainees 
relied too much on the CPOE to create medication orders, and therefore were denied the 
experience of practical learning. 
c) Post-Market Surveillance (Adverse Drug Reaction Reporting) 
Adverse drug reactions (ADRs) result in a large number of hospital admissions 
and deaths (Lazarou, et. al., 1998; Green, Mottram, Rowe & Pirmohamed, 2000). Post-
market surveillance is a system of responding to adverse events in a population due to 
prescription medications. There are variations in how these systems are implemented 
worldwide, however the underlying process is one whereby health professionals report 
adverse drug reactions to a national body, which in turn monitors the frequency of 
adverse events in the population. 
In the United Kingdom (UK), the "Yell ow Card Scheme" is considered one of the 
leading drug surveillance systems in the world. The system is based on voluntary 
reporting by health professionals of adverse drug events to the Committee on Safety of 
Medicines (CSM). A team of experts at the CSM investigates these reports, and if there 
appears to be a high frequency of adverse events associated with a particular drug, 
appropriate regulatory action is taken. (Sweis & Wong, 2000). In the UK, new products 
are identified with an inverted black triangle on the packaging for the first two years it is 
on the market. All suspected adverse reactions are to be reported for these new drugs. For 
20 
established drugs, only serious or unusual reactions are reported (Heeley, Riley, Layton, 
Wilton & Shakir, 2001) 
The "Yellow Card Scheme" in the UK is not perfect. A prescription-event 
monitoring study by Mann (1998) estimated that only 58% of the forms were returned, 
and while this is a considerably higher rate of response than that of post-marketing 
surveillance systems in the US and Canada (approximately 10%), it still may contain 
sampling biases. For example, it is not known if there is any difference between 
physicians who return the forms, and those who do not return the form. 
Despite the limitations in post-marketing drug surveillance, the data collected 
from such systems is essential given the limited information available on new drugs 
entering the market. In pre-market clinical trials subjects are carefully selected to have 
only one disease being treated by one drug. As a result of this selective sampling, few of 
the subjects are representative of the general population (Mann, 1998; Grootheest, Graaf 
& Berg, 2003; Puijenbroek, Diemont & Grootheest, 2003). It is not uncommon for a drug 
to get marketing approval only to be subsequently removed from the market because of a 
high incidence of ADRs (Boyd, 2002; Ajayi, Sun & Perry, 2000). 
While post market surveillance has proven to be an effective means for 
identifying adverse drug events not detected in pre-market trials, under-reporting of such 
events is frequent. Sweis & Wong (2000) found that 49 of the 129 pharmacists (39%) 
who had identified an ADR did not report them. It is estimated that reporting of serious 
ADR's rarely exceeds 10% (Williams & Feely, 1999). Factors which are thought to 
influence under-reporting of ADR's include lack of confidence that the drug actually 
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caused the ADR, the ADR being trivial or too well known, and the extra time it takes to 
complete ADR reports (Eland, Belton, van Grootheest, Meiners, Rawlins & Stricker, 
1999). Further education and training may be required to increase reporting (Green, 
Mottram, Rowe & Pirmohamed, 2001). 
Medication therapies are becoming increasingly more complex; community 
pharmacists are now required to keep current on the vast amount of information now 
available (Tully & Seston, 2000). Pharmacists are becoming more involved in the process 
of patient care, and as a result they play an important role in reviewing and monitoring 
prescribing, rather than simply dispensing medications. The electronic reporting of ADRs 
via a Pharmacy Network may be an effective means to identify a wide variety of adverse 
reactions to medications in a population. 
d) Prescription Profiling 
Increasing costs and over utilization of prescription medications are concerns for 
both government subsidized drug programs and health professionals. Over-utilization of 
drugs contributes to the added burden of drug-induced disease in the general population 
(Moore, Lecointre, Noblet & Mabille, 1998). Prescription profiling can improve drug 
utilization and minimize drug duplication and interaction, while at the same time control 
costs (Cook Jr & Schuyler, 1985). Generally, prescription profiles contain demographic 
and medication information on each patient. Medication information on a prescription 
profile may include the type of medication, date of prescribing and dispensing, refill 
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dates, quantity, strength, and specific directions for administering the drug. As well as 
providing a heath professional with a list of current medications, most prescription 
profiles provide a 6-12 month prescribing history. Drug profiles have enhanced patient 
care through the identification of drug over/under-utilization, duplication, interactions 
and toxicity. A significant reduction in the average number of drugs prescribed per 
patient has been linked to the use of prescription profiles (Laucka & Hoffman, 1992; 
Britton & Lurvey, 1991). Prescription profiles have been found to provide valuable 
information to health professionals that was not previously available, while significantly 
reducing the amount of time spent by a health professional in determining a patient's 
drug history (Koepsell, Helfand, Diehr, Gurtel, Gieser & Tompkins, 1983). With the 
advancement of pharmacy networks, today's profiles can contain information on all 
prescriptions dispensed to a patient, regardless of where that prescription was filled. 
Currently, in Newfoundland and Labrador, portions of a patient's medication 
profile is dispersed among all pharmacies which a patient uses to fill prescriptions, and 
any hospitals in which the patient may have received drugs. The proposed Pharmacy 
Network in Newfoundland and Labrador would link all community and hospital 
pharmacies, resulting in health professionals having immediate access to all medications 
dispensed to a patient (Stakeholder Consultation Presentation, NLCHI, 2002). Today's 
technology allows for complete medication profiles which can be used by health 
professionals in providing optimum care for their patients 
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Perceived Value of a Pharmacy Network to Community Pharmacists Pre-
Implementation 
No studies that investigated the perceived value to community pharmacists of a 
Pharmacy Network prior to its implementation could be located. However, a study by 
Kozyrskyj, et al., (1998) measured perceived value of Manitoba's DPIN system to 
community pharmacists approximately 3 years after the Pharmacy Network had been 
implemented. Krozyskyi, et al., found that 80% of community pharmacists surveyed 
agreed the DPIN system was beneficial, with the vast majority (94%) feeling that drug 
utilization reviews were an important function provided by the DPIN system. The 
identification of drug-related problems was felt to be beneficial by 87% of the 
pharmacists surveyed. This study also found areas where pharmacists were less than 
positive about the value of the DPIN system. The major concern, expressed by 75% of 
the pharmacists was that they were not reimbursed for DUR services. Other concerns 
identified were that the DPIN interfered with client service (29%), and that they were too 
busy to use the DPIN (26%). 
Payment for Pharmaceutical Care 
In the last 10 years, pharmacists have made enormous advances in the delivery of 
patient care through the development and implementation of a wide range of 
pharmaceutical care services. Pharmaceutical care includes counseling, monitoring 
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outcomes, assessing medication appropriateness based on a patient's medical history, and 
working with physicians to ensure that the best possible medications are prescribed 
(Larson, 2000). Despite these enhancements in patient care services, pharmacists face 
difficulties in obtaining compensation for these services. In Newfoundland and Labrador, 
community pharmacists receive no compensation from the provincial government for 
pharmaceutical care services they provide clients covered under the Newfoundland and 
Labrador Prescription Drug Program (NLPDP). The NLPDP is the provincial 
government drug program that provides prescription drug coverage to low-income 
residents of the province. Even in jurisdictions where pharmacists are compensated for 
pharmaceutical care services, the service is not universal. Pharmacists may feel that such 
services are part of their everyday responsibilities and should not be subject to additional 
fees. The argument that no other health professional would provide such services without 
appropriate compensation appears to be difficult to accept by pharmacists (Bennett et al., 
2000). As well, pharmacists may lack confidence in their ability to provide 
pharmaceutical care and therefore are reluctant to charge for services they feel they are 
not qualified to provide (Bennett, et al., 2000). Still other barriers include the lack of 
private counseling areas within pharmacies, and the unease of phanriacists regarding the 
reaction of physicians to their enhanced role (Larson, 2000). 
It is interesting to note that many patients are willing to pay for such services if 
they believe it would reduce the risk of adverse events, and that the willingness to pay 
increased proportionately with the decrease in risk of adverse events (Suh, 2000). And 
while payment by private insurance companies for pharmaceutical care is gaining 
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acceptance, the focus of third party payers has generally been on dispensing fees, rather 
than pharmaceutical care (Miller & Ortmeier, 1995; Larson, 2000). 
Another source of revenue for pharmacists who provide pharmaceutical care is 
self-funded commercial employers. Employers with self-funded medical plans pay 
directly from their income (or assets) for medical claims on behalf of their employees. 
These employers are supportive of pharmaceutical care programs, as they reduce 
absenteeism due to illness, and therefore increase net profits (Bennett, et al., 2000). Many 
large commercial companies in the United States now have self-funded health plans for 
their employees (Employee Benefits Research Institute, Washington DC., 2000). While 
no self-funded studies in Canada could be found, it is reasonable to assume that such 
private company programs exist here as well. 
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Target Population 
CHAPTER II 
METHODS 
The target population for this study was all 435 community pharmacists 
practicing in Newfoundland and Labrador in December 2002. For the purpose of this 
study, a community pharmacist was defined as a pharmacist who was employed in a 
community pharmacy which is either operated independently or part of a national chain. 
Pharmacists employed in either an educational or hospital setting were not part of the 
target population for this study. 
Instrument 
A four-part questionnaire was developed in consultation with the researcher's 
supervisory committee, NLCHI's Pharmacy Scoping Team, and through a literature 
search. The first section of the questionnaire captured demographic information, the 
second part identified those functions which community pharmacists feel are most crucial 
to the success of the Pharmacy Network, the third section measured support specific to 
reimbursement for pharmaceutical services, while the fourth section dealt with general 
issues. A five-point Likert scale and a dichotomous (e.g., yes/no) approach were used to 
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solicit responses for the majority of questions. An opportunity to provide general 
comments was provided by an open-ended question at the end of the questionnaire. 
A draft of the questionnaire was presented informally to a group of five 
community pharmacists. The primary objective of the meeting was to obtain feedback 
from the pharmacists on the relevance of the survey questions in relation to the overall 
objectives of the study. After being given an overview of the study objectives, an 
opportunity was provided to recommend adding, dropping or modifying questions, and to 
suggest improvements to the general layout of the questionnaire. Based on feedback 
provided by the community pharmacists, minor revisions were made to the questionnaire, 
and the revised questionnaire was presented to the supervisory committee for approval. 
The compamon cover letters (Appendix B), the final survey questionnaire 
(Appendix C), and completed Human Investigation Committee (HIC) application were 
submitted to Memorial University's HIC for ethics approval. Ethics approval was 
received on December 2, 2002 (Appendix D). In order to safeguard the privacy of 
respondents, all data were entered into SPSS and stored on the investigator's computer, 
which was password protected. The computer was located in an office with a door that 
can be locked when vacated. Other than the investigator, no other person was authorized 
to access this database. The completed questionnaires were stored in a locked filing 
28 
cabinet in the investigator's office. No personal identifiers were attached to the 
completed questionnaires or computer files. 
Data Collection 
Upon receiving ethics approval, a survey package was mailed out to the 435 
community pharmacists in the province of Newfoundland and Labrador. The 
Newfoundland Pharmaceutical Association (NPhA) provided the mailing address of all 
pharmacies (n = 171) in the province, as well as the names of the pharmacists employed 
in each of these pharmacies. This mailing list is comprehensive, as all practicing 
pharmacists in Newfoundland and Labrador are required to register with the NPhA. To 
encourage pharmacists to respond, the survey was anonymous and a stamped return 
envelope was provided with each survey package. A unique random number was 
assigned to each return envelope and to the original mailing list of 435 community 
pharmacists. The first mail-out of 435 questionnaires was carried out on December 11, 
2002. The Executive Secretary at NLCHI was responsible for maintaining the mailing 
list, and identifying non-responses. When a completed questionnaire was returned, the 
secretary removed that respondent's name from the mailing list by cross-referencing the 
random number on the return envelope to the corresponding random number on the 
mailing list. Once a respondent in the first mail-out was identified, the secretary 
destroyed the corresponding return envelope. The researcher was only provided the 
anonymous questionnaires. 
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At the end of three weeks the total number of questionnaires returned was 178, for 
a 40.9% response rate. On January 3, 2003, approximately three weeks after the initial 
mail-out, a second mail-out to non-respondents was carried out. On January 30, 2003, 
approximately four weeks after the second mail-out, the last completed questionnaire was 
received. The second mail-out provided an additional 41 completed questionnaires, for a 
total response rate of 50.3% (219/435) 
Data Analysis 
Responses were investigated usmg descriptive statistics (i.e., Pearson's Chi-
square and Fisher's exact tests, and t-tests for equality of means). Given the relatively 
small sample size (n=219), and the high proportion of subjects responding towards either 
end of the 5-point likert scale, the 5-point scale was collapsed into a dichotomous 
variable for the purpose of developing 2x2 contingency tables. Those subjects responding 
either "strongly agree" or "somewhat agree" were recoded as "agree", while subjects 
responding "neither agree nor disagree", "somewhat disagree" or "strongly disagree" 
were recoded as "do not agree". This dichotomous "Level of Agreement" variable was 
investigated using Chi-square tests across age groupings, gender, education, years 
practicing and place of business. A p-value of 0.05 was chosen for determining statistical 
significance. 
An example ofhypothesis testing employed in the analysis is as follows: 
H0 : The age of the pharmacists (age groups) and their perceptions that DURs 
are of limited value without complete profile are independent; 
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vs 
Ha: The age of the pharmacists (age groups) and their perceptions that DURs 
are of limited value without complete profile are not independent 
Upon running the chi-square test, if the resulting p-value was< 0.05 we rejected 
the null hypothesis (H0 ) and accepted the alternative hypothesis CHa), that the perception 
that DURs are of limited value without complete profile is dependent on the age 
(grouping) of the community pharmacist. Conversely, if the p-value was => 0.05 we 
could not reject the null hypothesis and concluded that the perception that DURs are of 
limited value without complete profile is not dependent of the age (grouping) of the 
community pharmacist. The hypothesis for each chi-square table presented in the results 
section followed this approach. 
To measure the internal consistency of the survey questionnaire reliability 
analysis was carried out on questions related to community pharmacists' perceived 
support for CPOE, DURs and Cognitive Services. Reliability analysis provides 
information about the relationships (or internal consistency) between any number of 
questions asked about a specific topic (e.g., CPOE). Using Cronbach's Alpha as the 
model it was found that each of these three scales used in the survey questionnaire had a 
high internal consistency: CPOE (0.86), DURs (0.80) and Cognitive Services (0.89). 
The variable "Years Practicing" was selected for comparison to identify 
differences that may exist between the perceived value to pharmacists of a Pharmacy 
Network and number of years practicing in a community pharmacy. Years practicing was 
also an indicator investigated by Conard, Fortenberry, Blythe & Orr (2003) in their study 
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of pharmacists' attitudes towards providing services to adolescents. For this current study 
the variable "Years Practicing" was re-coded to pharmacists with less than 12 years and 
12 or more years experience, as 12 years experience was the median number of years 
practicing for the sample. In 1990, the 4-year Diploma Program in Pharmacy was 
replaced with the current 5-year Bachelor of Science Degree offered by Memorial 
University of Newfoundland. In 1995, the first B.Sc. graduates entered the workforce, 
and in 2003 these graduates would have at most 8 years experience in a community 
pharmacy. By selecting the median cut-off of 12 years, the derived indictor "Years 
Experience" included pharmacists with both levels of education, while at the same time 
minimizing the potential for small cell counts (i.e., < 5) when generating 2x2 contingency 
tables. 
Using the median age of the study sample as the cut-off, the continuous variable 
"Age" was recoded to a dichotomous "Age Group" variable; under the age of 37 and 37 
years and older. A study by Dunlop & Shaw (2002) in New Zealand, that investigated 
community pharmacists' perceptions' on pharmaceutical care, looked at the differences 
in perception above and below the mean age of pharmacists. For this study the median 
age was selected as the measure for central tendency given the large standard deviation 
for the mean age of the study sample ( 38.5 ± 10.3). 
The variable "Place of Business" was selected for companson to identify 
differences in perceived value to a Pharmacy Network that may exist between 
pharmacists who work in an urban or rural community. Urban and rural differences were 
also studied by Conard, et al., (2003), although their cutoff for a rural area was a 
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population of< 30,000. For this study "Place of Business" was derived from the survey 
question "Is this pharmacy located in: (a) a city, (b) a community population> 10,000, 
but not a city, (c) a community < 10,000". Categories (a) and (b) were recoded to 
"Urban" and category (c) was re-labeled "Rural". The cut-off between urban and rural 
communities based on a population of 10,000 used in this study is consistent with 
Statistics Canada's definition of urban/rural communities (Rural and Small Town Canada 
Analysis Bulletin, Vol. 3, No.3 November 2001). 
Education was chosen for comparison as we wished to see if there were 
differences in perception between those pharmacists with a Pharmacy Diploma and those 
with a Bachelor of Science Degree. 
All resulting cross-tabulations were 2x2 contingency tables where variables of 
interest were a combination of nominal (e.g., gender) and ordinal (i.e., level of 
agreement), or both were ordinal (e.g., age group and level of agreement). Given the 
contingency tables for this study sample are large (n = 217) the Pearson's Chi-square 
statistic was used to determine significance. In eleven (11) 2x2 contingency tables, the 
expected cell count for at least one cell was less than five. For these tables the 2-sided 
Fisher's exact test was used. All analyses were carried out using SPSS version 11.5 
(SPSS Inc., Chicago, IL) 
The single open ended question was analyzed by the researcher using a method of 
content analysis as described in the Methodology Manual published by the Texas State 
Auditor's Office (USA), 1995. Content analysis is a method used to determine the 
content of written communications by using a systematic, objective, and quantitative 
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procedure and is especially useful in quantifying responses to open-ended survey 
questions. There are five common coding units in content analysis: (1) words, (2), 
themes, (3) character, (4) items, and (5) space-and-time measures. In analyzing the open 
ended question asked in this study, two coding units were utilized; words and themes. 
Within the context of the study, words were classified into distinct groups (e.g., cost for 
software), and then these word groupings were aggregated to create separate themes (e.g., 
cost). 
In an effort to determine whether the sample of respondents was representative of 
the population, the Newfoundland Pharmaceutical Association was asked to provide 
summary demographic statistics for their membership. Only gender, current position 
(i.e., manager, staff or relief) and education (B.Sc. or Diploma) were available. 
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Response Rate 
CHAPTER III 
FINDINGS 
The survey was conducted from Dec 11, 2002 to January 30, 2003. Of the 435 
surveys mailed out, 219 community pharmacists responded. In two cases the respondents 
did not complete the main part of the questionnaire, and only provided written comments. 
These two surveys were excluded from the quantitative analysis of the study. Therefore, 
the adjusted response rate to the survey was 49.9% (217/435). 
Characteristics of the Sample 
As shown in Table 3.1, 55.6% of community pharmacists who responded to the 
survey were male, ranging in age from 25-70 (mean= 41.6); female respondents were 
generally younger having an age range 24-62 (mean= 34.7). Approximately 37% percent 
of males and 10% of females were over the age of 44. There were almost equal 
proportions of job positions, with 45.6% being managers or owners, and 48.8% being 
staffpharmacists; 5.5% were relief pharmacists. There were similar gender distributions 
for the sample compared to the population, however there was a higher proportion of 
managers/owners in the sample than in the population. 
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Table 3.1 
Characteristics of the Sample 
Gender, Age and Current Position 
Male 
<25 
25-34 
35-44 
45-54 
55-64 
65+ 
Mean Age 
Median Age 
Range in Years 
Female 
Manager/Owner 
Staff 
Relief 
< 25 
25-34 
35-44 
45-54 
55-64 
65+ 
0 
36 
35 
27 
12 
3 
113 
113 
113 
3 
48 
34 
8 
1 
0 
94 
99 
106 
12 
* Newfoundland Pharmaceutical Association (NPhA) 
0.0% 
31.9% 
31.0% 
23.9% 
10.6% 
2.7% 
41.6 
42.0 
25-70 
3.2% 
51.1% 
36.2% 
8.5% 
45.6% 
48.8% 
5.5% 
nla 
nla 
nla 
nla 
nla 
nla 
nla 
nla 
nla 
nla 
nla 
nla 
nla 
nla 
nla 
nla 
33.6% 
65.7% 
0.7% 
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As shown in Table 3.2, 58.9% of the respondents had obtained a Bachelor of 
Science {B.Sc.) in Pharmacy, while 41.1% graduated from college with a diploma in 
pharmacy. This distribution was the reverse in the population, with 41.0% of community 
pharmacists having a B.Sc. and 59.0% having graduated with a diploma. Managers 
worked longer hours per week than both staff and relief pharmacists (means 41.0, 35.9 
and 29.3, respectively) with 30.3% of managers and 2.8% of staff pharmacists working 
more than 40 hours a week. 
Table 3.2 
Characteristics of the Sample 
Education and Hours Worked 
Manager 
<35 13 13.1% 
35-40 56 56.6% 
41+ 30 30.3% 
Mean Hours Worked 99 41.0 
Median Hours Worked 99 40.0 
Range in Hours 99 8.0-80 
Staff 
<35 20 18.9% 
35-40 83 78.3% 
41+ 3 2.8% 
Mean Hours Worked 106 35.9 
Median Hours Worked 106 40.0 
Range in Hours 106 8.0-45.0 
Relief 
<35 6 50.0% 
35-40 4 33.3% 
41+ 2 16.7% 
Mean hours Worked 12 29.3 
Median hours Worked 12 32.5 
in Hours 12 9.0-50.0 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
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Table 3.3 presents indicators based on years practicing in a community pharmacy. 
Male pharmacists averaged 17.3 years experience (range 1-49), whereas females 
averaged 11.5 years (range 1-41). A higher proportion of male pharmacists were found to 
have more than 21 years experience than their female counterparts (41.2% versus 19.8%). 
Population values for number of years practicing was not available. 
Table 3.3 
Characteristics of the Sample 
Years Practicing 
Male 
<5 21 
5-10 19 
11-15 16 
16-20 14 
21+ 49 
Mean Years Practicing 119 
Median Years Practicing 119 
Range in Years Practicing 119 
Female 
<5 26 
5-10 28 
11-15 10 
16-20 13 
21+ 19 
Mean years practicing 96 
Median Years Practicing 96 
96 
17.6% 
16.0% 
13.4% 
11.8% 
41.2% 
17.3 
17.0 
1-49 
27.1% 
29.2% 
10.4% 
13.5% 
19.8% 
11.5 
9.0 
1-41 
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Table 3.4 presents indicators based on years working in a community pharmacy. 
Overall, the average time a community pharmacist was employed at the pharmacy during 
the time of the survey was 7.1 years, with a further 7.1 years experience in another 
community pharmacy. Population values for number of years practicing was not 
available. 
Table 3.4 
Characteristics of the Sample 
Years Working 
Current Pharmacy 
<5 Years 106 
5-10 years 54 
11+ Years 57 
Mean Years Working 217 
Median Years Working 217 
Range in Years Working 217 
Previous Community 
Pharmacy 216 
<5 Years 113 
5-10 Years 49 
11+ Years 54 
Mean years working 216 
Median Years Working 216 
216 
48.8% 
24.9% 
26.3% 
7.1 
5.0 
0-38 
7.1 
52.3% 
22.7% 
25.0% 
7.1 
4.0 
0-45 
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As presented in Table 3.5, all pharmacists worked either in a chain store (66.2%) 
or m an independent store (33.8%), with approximately half (47.7%) working in 
pharmacies located in communities with populations less than 10,000. A minority of 
pharmacists worked in more than one store (12.9%), with relief pharmacists having this 
work arrangement more often than managers and staff (58.3%, 8.1% and 12.3%, 
respectively) The majority of respondents (86.6%) worked in pharmacies that employed 
1-3 pharmacists. Population values for these indicators were not available. 
Table 3.5 
Characteristics of the Sample 
Type of Pharmacy, Working in More than One Store, 
Community Population and Number of Pharmacists Working in Pharmacy 
One 
Two 
Three 
Four or more 
27 
71 
89 
29 
12.5% 
32.9% 
41.2% 
13.4% 
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Perceived Value of Pharmacy Network Functions 
Section II of the questionnaire measured the perceived value to community 
pharmacists of four specific Pharmacy Network functions: 1) drug utilization reviews, 2) 
computerized physician order entry, 3) post-market surveillance (adverse drug reaction 
reporting), and 4) prescription profiling. As well as providing descriptive measures, Chi-
square tests of significance were performed to determine statistical significance in the 
perceived value of each of these pharmacy network functions with respect to the five 
demographic variables; age, gender, education, years practicing and place of business 
(i.e., urban or rural). 
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1. Drug Utilization Review 
Table 3.6 presents the perceived value to community pharmacists of including drug 
utilization reviews (DURs) in the development of the Pharmacy Network. The majority 
of respondents (89.4%) agreed DURs would have limited value unless carried out on the 
complete patient profile. With access to complete medication profiles, 91.3% respondents 
agreed that DURs would significantly reduce prescribing problems such as drug 
interactions and drug duplication, while 80.2% believed DURs would significantly 
reduce hospital admissions. Overall, 90.3% of community pharmacists agreed DURs 
would be an important function of the Pharmacy Network, although only 69.6% believed 
DUR services would be valued by their clients. 
Table 3.6 
Pharmacists' Perception of the Value of Drug Utilization Reviews 
(n=217) 
Drug Utilization Total Level of Agreement 
Reviews Response Strongly Somewhat Neither Agree Somewhat 
Agree Agree or Disagree Disagree 
Limited value without 
complete patient profile 217 134 (61.8) 60 (27.6) 13 (6.0) 8 (3.7) 
Will reduce prescribing 
problems 217 118 (54.4) 80 (36.9) 14 (6.5) 5 (2.3) 
Will reduce hospital 
admissions 217 82 (37.8) 92 (42.4) 37 (17.1) 5 (2.3) 
Clients will value DUR 
services 217 57 (26.3) 94 (43.3) 52 (24.0) 13 (6.0) 
DUR important function 
ofPharmacyNetwork 217 114 (52.5) 82 (37.8) 16 (7.4) 2 (0.9) 
Strongly 
Disagree 
2 (0.9) 
0 (0.0) 
1 (0.5) 
1 (0.5) 
3 (1.4) 
42 
Table 3.7 presents the results of the tests for significance when community 
pharmacists' level of agreement that DURs would have limited value without having a 
complete patient profile were cross-tabulated by the five select demographic variables. 
No statistically significant difference between age groups, gender, education, years 
practicing or place of business were identified. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.7 
Pharmacists' Perception of Drug Utilization Reviews 
Being of Limited Value Without a Complete Patient Profile, 
by Select Demographics 
Level p-value 
0.800 
0.061 
0.268 
0.899 
0.817 
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Table 3.8 presents the results of the tests for significance when community 
pharmacists' level of agreement that DURs would reduce prescribing problems were 
cross-tabulated by the five select demographic variables. No statistically significant 
difference between age groups, gender, education, years practicing or place of business 
were identified. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.8 
Pharmacists' Perceptions that Drug Utilization 
Reviews will Reduce Prescribing Problems, 
by Select Demographics 
Level p-value 
0.213 
0.096 
0.689 
0.682 
0.157 
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Table 3.9 presents the results of the tests for significance when community 
pharmacists' level of agreement that DURs will be an important function of the 
Pharmacy Network were cross-tabulated by the five select demographic variables. A 
statistically significant difference was found for gender, suggesting that a larger 
proportion of female pharmacists feel that DURs will be an important function of the 
Pharmacy Network 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.9 
Pharmacists' Perceptions that Drug Utilization Reviews 
will be an Important Function of the Pharmacy Network, 
by Select Demographics 
Level p-value 
0.213 
0.045 
0.443 
0.702 
0.246 
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Table 3.10 presents the results of the tests for significance when community 
pharmacists' level of agreement that DURs will significantly reduce hospital admissions 
were cross-tabulated by the five select demographic variables. No statistically significant 
difference between age groups, gender, education, years practicing or place of business 
were identified. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.10 
Pharmacists' Perceptions that Drug Utilization Reviews 
will Significantly Reduce Hospital Admissions, 
Level 
by Select Demographics 
Will significantly reduce hospital 
admissions p-value 
0.750 
0.159 
0.199 
0.633 
0.086 
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Table 3.11 presents the results of the tests for significance when community 
pharmacists' level of agreement that their clients would value the services they would be 
able to provide through their use of the Pharmacy Network were cross-tabulated by the 
five select demographic variables. A statistically significant difference was found 
between age groups, gender and education, suggesting that a larger proportion of older 
pharmacists, female pharmacists, and/or pharmacists who graduated with a diploma 
perceive their clients would value the services they would be able to provide through 
their use of the Pharmacy Network. 
Variable 
Age 
Gender 
Education 
Years 
Practicing 
Place of 
Business 
Table 3.11 
Pharmacists' Perception that Clients will Value 
Drug Utilization Review Services, 
by Select Demographics 
Clients will value 
Level p-value 
0.043 
0.006 
0.041 
0.130 
0.369 
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2. Computerized Physician Order Entry 
Table 3.12 presents the perceived value to community pharmacists of a 
Computerized Physician Order Entry (CPOE) function in enhancing patient safety. 
Approximately two-thirds of respondents agreed that CPOE would be useful by 
providing default doses for normal conditions, while 71.1% felt there was value in having 
access to information on medication appropriateness. The majority of respondents agreed 
the ability to automatically check for dose ceilings (83 .1%) and screen for drug 
interactions (83.7%) were important functions. More than 80% of respondents believed 
checking on allergy information, having access to complete profiles and providing real 
time information were valuable tools. The greatest perceived enhancement to patient 
safety of the CPOE (97 .2%) was the removal of problems associated with errors in 
interpreting physician handwriting. 
Table 3.12 
Pharmacists' Perception of the Value of 
Computerized Physician Order Entry 
(n=217) 
Levelofi\greement 
CPOE will enhance Total Strongly Somewhat Neither Agree Somewhat 
Patient safety by: 
Agree Agree or Disagree Disagree 
Providing default doses 214 41 (19.2) 108 (50.5) 49 (22.9) 11 (5.1) 
Removing problems with 
illegible handwriting 215 178 (82.8) 31 (14.4) 3 ( 1.4) 3 (1.4) 
Checking dose ceilings 214 60 (28.0) 118 (55.1) 29 (13.6) 5 (2.3) 
Checking allergy information 215 71 (33.0) 112 (52.1) 21 ( 9.8) 11 (5.1) 
Screening for drug interactions 214 84 (39.3) 95 (44.4) 23 (10.7) 11 (5.1) 
Providing complete profile 213 113 (53.1) 68 (31.9) 23 (10.8) 8 (3.8) 
Providing real time information 213 74 (34.7) 102 (47.9) 32 (15.0) 4 (1.9) 
Providing information on 
medication appropriateness 214 56 (26.2) 97 (45.3) 49 (22.9) 11 (5.1) 
Strongly 
Disagree 
5 (2.3) 
0 (0.0) 
2 (0.9) 
0 (0.0) 
1 (0.5) 
1 (0.5) 
1 (0.5) 
1 (0.5) 
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Table 3.13 presents the results of the tests for significance when community 
pharmacists' level of agreement that CPOE will result in enhanced safety by providing 
default doses for normal conditions were cross-tabulated by the select demographic 
variables. No statistically significant difference between age groups, gender, education, 
years practicing or place of business were identified. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.13 
Pharmacists' Perception that CPOE will Enhance 
Patient Safety by Providing Default Doses, 
Level 
by Select Demographics 
Providing default doses for 
normal conditions p-value 
0.807 
0.548 
0.880 
0.964 
0.145 
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Table 3.14 presents the results of the tests for significance when community 
pharmacists' level of agreement that CPOE will result in enhanced safety by removing 
problems with illegible handwriting were cross-tabulated by the select demographic 
variables. A statistically significant difference was found between gender, suggesting that 
a larger proportion of female pharmacists feel that CPOE will result in enhanced safety 
by removing problems with illegible handwriting. It should be noted that all 2x2 tables in 
Table 3.14 had at least one cell where the expected cell count was less than 5, therefore 
the 2-sided Fisher's exact test was used to determine significance. 
Table 3.14 
Pharmacists' Perceptions that CPOE will Enhance Patient Safety by Removing 
Problems with Illegible Handwriting, by Select Demographics 
Variable 
Age 
Gender 
Education 
Years 
Practicing 
Place of 
Business 
Level 
* 2-Sided Fisher's Exact Test 
p-value 
0.212* 
0.034* 
1.000* 
0.683* 
0.431* 
50 
Table 3.15 presents the results of the tests for significance when community 
pharmacists' level of agreement that CPOE would enhance patient safety by checking for 
dose-ceilings were cross-tabulated by the five select demographic variables. There was a 
statistically significant difference found for years practicing, suggesting that a larger 
proportion of community pharmacists with 12+ years experience value the function of 
checking for dose-ceilings than community pharmacists with <12 years experience. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.15 
Pharmacists' Perceptions that CPOE will Enhance 
Patient Safety by Checking for Dose Ceilings, by 
Select Demographics 
p-value 
0.089 
0.487 
0.055 
0.034 
0.652 
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Table 3.16 presents the results of the tests for significance when community 
pharmacists' level of agreement that CPOE would enhance patient safety by checking for 
allergy information were cross-tabulated by the five select demographic variables. No 
statistically significant difference between age groups, gender, education, years practicing 
or place of business were identified. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.16 
Pharmacists' Perceptions that CPOE will Enhance 
Patient Safety by Checking Allergy Information, 
by Select Demographics 
p-value 
1.000 
0.395 
0.737 
0.744 
0.112 
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Table 3.17 presents the results of the tests for significance when community 
pharmacists' level of agreement that CPOE would enhance patient safety by screening for 
drug interactions were cross-tabulated by the five select demographic variables. No 
statistically significant difference between age groups, gender, education, years practicing 
or place of business were identified. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.17 
Pharmacists' Perception that CPOE will Enhance 
Patient Safety by Screening for Drug Interactions, 
by Select Demographics 
p-value 
0.869 
0.590 
0.833 
0.782 
0.377 
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Table 3.18 presents the results of the tests for significance when community 
pharmacists' level of agreement that CPOE would enhance patient safety by providing a 
complete patient profile were cross-tabulated by the five select demographic variables. A 
statistically significant difference was found for place of business, suggesting that a 
larger proportion of pharmacists who work where there is a high volume of prescriptions 
dispensed (i.e, urban centres) value a complete patient profile. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.18 
Pharmacists' Perceptions that CPOE win Enhance 
Patient Safety by Providing a Complete Patient Profile, 
by Select Demographics 
Level p-value 
0.510 
0.605 
0.736 
0.617 
0.021 
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Table 3.19 presents the results of the tests for significance when community 
pharmacists' level of agreement that CPOE would enhance patient safety by providing 
real time information on dose algorithms were cross-tabulated by the five select 
demographic variables. No statistically significant difference between age groups, 
gender, education, years practicing or place of business were identified. 
Variable 
Age 
Gender 
Education 
Years 
Practicing 
Place of 
Business 
Table 3.19 
Pharmacists' Perceptions that CPOE will Enhance 
Patient Safety by Providing Real Time Information, 
by Select Demographics 
p-value 
0.707 
0.833 
0.688 
0.807 
0.127 
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Table 3.20 presents the results of the tests for significance when community 
pharmacists' level of agreement that CPOE would enhance patient safety by providing 
information on medication appropriateness were cross-tabulated by the five select 
demographic variables. A statistically significant difference was found for place of 
business, suggesting that a larger proportion pharmacists who work where there is a high 
volume of prescriptions dispensed (i.e., urban centres) value the ability to identify 
medication appropriateness based on patients medical history. 
Table 3.20 
Pharmacists' Perception that CPOE will Enhance 
Patient Safety by Providing Information on Medication Appropriateness, 
by Select Demographics 
Variable p-value 
Age 0.609 
Gender 0.231 
Education 0.463 
Years 0.778 
Practicing 
Place of 0.047 
Business 
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3. Post-Market Surveillance {Adverse Drug Reaction Reporting) 
Community pharmacists in this study reported an average of 2.5 adverse drug 
reactions (ADRs) a year. A statistically significant difference in the average number 
ADRs reported was found between age groups, gender, education and years practicing, 
suggesting that a larger proportion of pharmacists who are older, are male, graduated 
with a Diploma in Pharmacy, and/or have more experience, will report more ADR's. 
Table 3.21 
Average Number of Adverse Drug Reactions (ADRs) 
Reported in One Year 
Variable Level 
Business 
Pharmacists 
Responding 
MeanADRs 
Reported p-value 
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The majority of community pharmacists (87.6%) indicated they would report 
more adverse events if it could be done electronically through the Pharmacy Network. As 
shown in Table 3.22, there was no statistically significant difference in the perceived 
potential for increased reporting of ADRs between age groups, gender, education, years 
practicing, or place of business. 
Table 3.22 
Pharmacists' Perception of the Likelihood of 
Reporting More Adverse Drug Reactions if Available 
Electronically Through the Pharmacy Network, by Select Demographics 
Variable p-value 
Age 0.367 
Gender 0.258 
Education 0.156 
Years 0.055 
Practicing 
Place of 0.070 
Business 
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4. Prescription Profiling 
In order to determine what medications a client is currently receiving, 59.9% of 
community pharmacists indicated they asked the client, 15.5% asked other health care 
providers, 12.5% asked members of the clients family, and 11.5% would use their own 
computer profile. To a lesser extent, community pharmacists would ask the client to bring 
all current medications into the pharmacy (9.5%). 
When asked if they knew the total number of medications that were prescribed to 
their patients, 34.6% of community pharmacists agreed that they did. As shown in Table 
3.23, there was no statistically significant difference in level of agreement that 
pharmacists' knew the total number of medications that were prescribed to their patients 
between age groups, gender, education, years practicing, or place of business. 
Table 3.23 
Pharmacists' Perceived Knowledge of the Total Number of Medications 
Prescribed to Patients, by Select Demographics 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Level p-value 
0.330 
0.542 
0.261 
0.423 
0.942 
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Payment for Pharmaceutical Care 
Table 3.24 presents the results when pharmacists were asked if they should be 
reimbursed for 1) providing counseling, 2) monitoring outcomes, 3) identifying 
medication appropriateness based on a patient's medical history, and 4) working with 
physicians to ensure the best possible medications are prescribed. The majority (89.3%) 
agreed they should be compensated for working with physicians in providing the best 
possible care for the client. There was also considerable agreement that compensation 
should be provided for monitoring outcomes (88.9%), identifying medication 
appropriateness (86.6%), and providing counseling (82.8%). 
Service 
Providing 
Counseling 
Monitoring 
Outcomes 
Medication 
Table 3.24 
Pharmacists' Perceptions Regarding Reimbursement, 
by Type of Pharmaceutical Service Provided 
(n=217) 
Level of Agreement 
Total Strongly Somewhat Neither Agree Somewhat 
Response Agree Agree or Disagree Disagree 
216 131 (60.6) 48 (22.2) 23 (10.6) 4 (1.9) 
216 146 (67.6) 46 (21.3) 17 (7.9) 2 (0.9) 
Appropriateness 216 124 (57.4) 63 (29.2) 18 (8.3) 6 (2.8) 
Working with 
Physicians 216 134 (62.0) 59 (27.3) 16 (7.4) 4 (1.9) 
Strongly 
Disagree 
10 (4.6) 
5 (2.3) 
5 (2.3) 
3 (1.4) 
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Table 3.25 presents the results of the tests for significance for community 
pharmacists' level of agreement that they should be reimbursed for providing counseling, 
cross-tabulated by the five select demographic variables. A statistically significant 
difference was found for gender, suggesting that a larger proportion of female 
pharmacists expect payment for counseling services. 
Variable 
Age 
Gender 
Education 
Years 
Practicing 
Place of 
Business 
Table 3.25 
Pharmacists' Opinion on Whether they Should 
Receive Payment for Providing Counseling, 
by Select Demographics 
p-value 
0.142 
0.002 
0.720 
0.267 
0.312 
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Table 3.26 presents the results of the tests for significant difference when 
community pharmacists' level of agreement that they should be reimbursed for 
monitoring patient outcomes were cross-tabulated with the five select demographic 
variables. A statistically significant difference was found for gender, suggesting that a 
larger proportion of female pharmacists feel they should be reimbursed for monitoring 
patient outcomes. It should be noted that the gender table in Table 3.26 had one cell 
where the expected cell count was less than 5, therefore the 2-sided Fisher's exact test 
was used to determine significance. 
Variable 
Age 
Gender 
Education 
Years 
Practicing 
Place of 
Business 
Table 3.26 
Pharmacists' Opinion on Whether they Should Receive 
Payment for Monitoring Outcomes by, 
Select Demographics 
* 2-sided Fisher's exact test 
p-value 
0.825 
0.004* 
0.503 
0.238 
0.128 
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Table 3.27 presents the results of the tests for significant difference when 
community phannacists' level of agreement that they should be reimbursed for 
identifying medication appropriateness based on a patient's medical history were cross-
tabulated with the five select demographic variables A statistically significant difference 
was found for age groups, gender, and years practicing suggesting that a larger proportion 
of younger phannacists, female pharmacists and/or those pharmacists with less years 
experience feel they should be reimbursed for identifying medication appropriateness. 
Variable 
Age 
Gender 
Table 3.27 
Pharmacists' Opinion on Whether they Should Receive Payment 
for Identifying Medication Appropriateness, 
by Select Demographics 
Education 
Place of 
Business 
p-value 
0.042 
0.005 
0.221 
0.039 
0.062 
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Table 3.28 presents the results of the tests for significant difference when 
community pharmacists' level of agreement that they should be reimbursed for working 
with physicians to ensure the best possible medications were cross-tabulated with the five 
select demographic variables. No statistically significant difference between age groups, 
gender, education, years practicing or place of business were identified. 
Variable 
Age 
Gender 
Education 
Years 
Practicing 
Place of 
Business 
Table 3.28 
Pharmacists' Opinion on Whether they Should 
Receive Payment for Working with Physicians, 
by Select Demographics 
p-value 
1.000 
0.058 
0.819 
0.586 
0.509 
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Additional Feedback 
When asked about training, 93.1% of community pharmacists agreed that a 
comprehensive orientation process would be required prior to implementation of the 
Pharmacy Network (see Table 3.29). A strong majority (95.0%) agreed the Pharmacy 
Network would benefit their practice, whereas only 65.0% believed it would improve 
their relationship with physicians. A minority of community pharmacists felt the 
Pharmacy Network would interfere with customer service (8.3%), while 31.3% believed 
their dispensary would be too busy to respond to the information available from the 
Pharmacy Network. Very few community pharmacists (17.2%) felt that the Pharmacy 
Network would not be relevant to them even if the majority of their clients were regular 
customers. 
Indicator 
Orientation required 
Benefit practice 
Too busy for Pharmacy 
Network 
Not relevant to clients 
Improve relationship 
with physicians 
Interfere with service 
Table 3.29 
Additional Feedback 
(n=217) 
Total Level of Agreement 
Response Strongly Somewhat Neither Agree Somewhat 
Agree Agree or Disagree Disagree 
217 143 (65.9) 59 (27.2) 12 (5.5) 2 (0.9) 
217 126 (58.1) 80 (36.9) 10 (4.6) 1 (0.5) 
217 5 (2.3) 63 (29.0) 55 (25.3) 63 (29.0) 
216 4 (1.9) 33 (15.3) 55 (25.5) 85 (39.4) 
217 42 (19.4) 99 (45.6) 60 (27.6) 14 (6.5) 
216 3 (1.4) 15 (6.9) 67 (31.0) 77 (35.6) 
Strongly 
Disagree 
1 (0.5) 
0 (0.0) 
31 (14.2) 
39 (18.2) 
2 (0.9) 
54 (25.0) 
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Table 3.30 presents the results of the tests for significant difference when 
community pharmacists' level of agreement that a comprehensive orientation process will 
be required prior to the implementation phase of the pharmacy network were cross-
tabulated with the five select demographic variables. No statistically significant 
difference between age groups, gender, education, years practicing or place of business 
were identified. It should be noted that the gender table in Table 3.30 had one cell where 
the expected cell count was less than 5, therefore the 2-sided Fisher's exact test was used 
to determine significance. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.30 
Pharmacists' Perceptions that an Orientation Process 
will be Required Prior to Pharmacy Network 
Implementation, by Select Demographics 
*2-sided Fisher's Exact Test 
p-value 
0.593 
0.184* 
0.652 
0.206 
0.463 
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Table 3.31 presents the results of the tests for significant difference when 
community phannacists' level of agreement that the Phannacy Network would benefit 
their practice were cross-tabulated with the five select demographic variables. A 
statistically significant difference was found for gender and place of business, suggesting 
that a larger proportion of female phannacists and/or those working in urban locations 
feel that the Pharmacy Network would benefit their practice. The age, gender, years 
practicing and place of business tables in Table 3.31 each had one cell where the 
expected cell count was less than 5, therefore the 2-sided Fisher's exact test was used to 
determine significance. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.31 
Pharmacists' Perceptions that a Pharmacy Network 
would Benefit their Practice, by Select Demographics 
* 2-sided Fisher's Exact test. 
p-value 
0.498* 
0.025* 
0.354 
0.102* 
0.028* 
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Table 3.32 presents the results of the tests for significant difference when 
community pharmacists' level of agreement that their dispensary would be too busy to 
respond to the information provided by the Pharmacy Network were cross-tabulated with 
the five select demographic variables. A statistically significant difference was found for 
gender, suggesting that a larger proportion of female pharmacists feel that they will be 
too busy to respond to the Pharmacy Network. 
Variable 
Age 
Gender 
Education 
Years 
Practicing 
Place of 
Business 
Table 3.32 
Pharmacists' Perceptions that the Dispensary 
will be too Busy to Respond to a Pharmacy Network, 
by Select Demographics 
p-value 
0.688 
0.022 
0.301 
0.688 
0.904 
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Table 3.33 presents the results of the tests for significant difference when 
community pharmacists' level of agreement that the Pharmacy Network would not be 
relevant to their clients as most would be regular customers, were cross-tabulated with 
the five select demographic variables. A statistically significant difference was found for 
education and place of business, suggesting that a larger proportion of pharmacists 
graduating with a diploma and/or those working in rural areas feel that the Pharmacy 
Network would not be relevant to their clients, as most would be regular customers. 
Variable 
Age 
Gender 
Education 
Years 
Practicing 
Place of 
Business 
Table 3.33 
Pharmacists' Perceptions that a Pharmacy Network would 
not be Relevant as all Clients are Regular Customers, 
by Select Demographics 
p-value 
0.117 
0.862 
0.014 
0.267 
0.007 
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Table 3.34 presents the results of the tests for significant difference when 
community pharmacists' level of agreement that the Pharmacy Network would improve 
their relationship with physicians were cross-tabulated with the five select demographic 
variables. No statistically significant difference between age groups, gender, education, 
years practicing or place of business were identified. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.34 
Pharmacists' Perceptions that a Pharmacy Network 
will Improve Relationship with Physicians, 
by Select Demographics 
Level p-value 
0.264 
0.610 
0.358 
0.818 
0.099 
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Table 3.35 presents the results of the tests for significant difference when 
community pharmacists' level of agreement that the Pharmacy Network would interfere 
with customer service were cross-tabulated with the five select demographic variables. 
No statistically significant difference between age groups, gender, education, years 
practicing or place of business were identified. 
Variable 
Age 
Gender 
Education 
Place of 
Business 
Table 3.35 
Pharmacists' Perceptions that a Pharmacy Network will 
Interfere with Customer Service, 
by Select Demographics 
p-value 
0.213 
0.982 
0.409 
0.667 
0.760 
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Response to Open Ended Question 
Of the 219 community pharmacists responding to the survey, 58 (26.5%) 
provided written comments when asked the open ended question "Are there any other 
comments you would like to make about your expectations of a Pharmacy Network, and 
how the Pharmacy Network would impact upon you or your pharmacy?". A content 
analysis of these responses using "words" and "themes" as coding units, as per content 
the methodology described in the Texas State Auditor's Office Methodology Manual 
(1995), found five common themes: 1) functions of the Pharmacy Network, 2) concerns 
about privacy and confidentiality, 3) costs associated with Pharmacy Network, 4) change 
management issues and 5) education and training. A sixth general category provides a 
summary of comments that did not fit into any of the five identified themes. 
1) Functions of the Pharmacy Network 
A major function identified by community pharmacists, that was not addressed in 
the questionnaire, was the ability to have immediate (electronic) submission of claims for 
prescriptions filled for clients covered under the Newfoundland and Labrador 
Prescription Drug Program (NLPDP). The NLPDP is the provincial government drug 
program that provides prescription drug coverage to low-income residents of the 
Province. The time currently required by community pharmacists to prepare, submit and 
receive payment for claims for NLPDP clients is felt to be considerable. It was also noted 
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that by providing an immediate adjudication function, special authorizations would be 
approved in a more timely manner for NLPDP clients. 
The implementation of a pharmacy network was also perceived as a means for 
addressing the problems associated with patients getting prescriptions from more than 
one doctor (double-doctoring), or patients getting prescriptions filled at more than one 
pharmacy (pharmacy shopping). In particular, the monitoring of double-doctoring 
through real time DURs was thought to be one way to reduce the abuse of prescription 
narcotics. 
Community pharmacists identified the value of including over the counter drugs 
(OTC's) in the patient profile. However it was also felt that the responsibility for 
capturing OTC information in the Pharmacy Network should fall to physicians. 
2) Privacy and Confidentiality 
The potential for abuse of the client's rights to privacy was of considerable 
concern to community pharmacists. Many respondents felt the Pharmacy Network should 
be used only as a tool by health professionals for the overall benefit of their patients. The 
Pharmacy Network should not be used by governments or insurance companies to 
identify patients who do not fit into what would be considered "normal" patterns of drug 
utilization; nor should it be used by large drug companies for marketing purposes. 
Several respondents, while expressing strong support for the Pharmacy Network, felt 
negative public opinion about a patient's right to privacy would prevent it from being 
implemented. Others felt privacy concerns could be addressed through appropriate 
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security measures and by following stringent rules regarding access to personal 
information. 
3. Cost 
Several issues concerning costs related to the Pharmacy Network were expressed. 
Many pharmacists believe they should not incur the costs for any software, hardware or 
training needed to connect to the Pharmacy Network. Several pharmacists indicated they 
might be forced to close if they are made to pick up the costs associated with accessing 
the Pharmacy Network. The Provincial Prescription Monitoring Program (PMP) was 
cited as one example where government-imposed programs that add costs to pharmacies 
are unlikely to succeed 1• Others questioned who would pay for building the Pharmacy 
Network, and whether any portion of the savings resulting from better utilization of 
prescription drugs would be funneled back to pharmacists. If no additional payments are 
forthcoming, dispensing fees would need to be significantly increased to compensate for 
the provision of enhanced services. 
1The PMP was set up by the Provincial Government to monitor utilization of prescriptions filled for drugs 
having a high potential for abuse and was later canceled. 
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4. Change Management 
Enhanced services that would be available through the Pharmacy Network raised 
several change management issues among community pharmacists. Considerable time is 
currently spent filling and dispensing prescriptions, and unless the Pharmacy Network 
reduces this time, pharmacists feel they will not have time to use the Pharmacy Network. 
Generally, pharmacists are paid for filling prescriptions, and it would be unrealistic to 
expect them to enter additional data required for the Pharmacy Network without 
receiving additional compensation. This was believed to be a potential obstacle to 
realizing the full benefits of the Pharmacy Network. The additional time entering data 
would also take away from the time pharmacists currently spend counseling their 
patients. The process of accessing the Pharmacy Network for each new prescription 
would also consume considerable time, especially in pharmacies that deal with large 
volumes of prescriptions. However, it was noted that the perceived problems of 
additional workload could be addressed by developing a Pharmacy Network that is fast, 
efficient and 'extremely' user friendly. 
The cooperation of physicians was also seen as a change management issue. If 
physicians do not welcome the input of pharmacists, and make themselves available for 
consultation, then the benefits of the Pharmacy Network will be substantially 
compromised. 
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5. Education and Training 
Pharmacists felt they would require considerable training with respect to how to 
use the Pharmacy Network prior to its implementation. Education of the public was also 
seen as a critical success factor, so that the public could see pharmacists as professional 
people who do more than move pills from one bottle to another. 
6. General 
The majority of comments provided by community pharmacists were in support 
of the Pharmacy Network. The focus on safety, enhanced patient outcomes and better 
utilization of scarce health care dollars were seen as just a few of the benefits to 
individual patients and to the province overall. A small minority (3.4%) felt the 
Pharmacy Network was a waste of time and that it would never work (e.g., "Another 
make work program!!"). Those opposing the development of the Pharmacy Network 
provided no specific reasons why they felt the Pharmacy Network would not be 
successful. 
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CHAPTER IV 
DISCUSSION OF RESULTS 
A discussion of the results summarizing community pharmacists' perceptions of 
1) drug utilization reviews, 2) computerized physician order entry, 3) post-market 
surveillance, 4) prescription profiling, 5) pharmaceutical care, and 6) payment for 
providing pharmaceutical care services is provided. Statistically significant differences in 
community pharmacists' perceptions when compared across age groups, gender, 
education, years practicing and place ofbusiness are also discussed (see Table 4.1). 
Table 4.1 
Summary of Tests for Significance 
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1) Perceived Value ofDrug Utilization Reviews 
The findings of this study indicate that community pharmacists believe drug 
utilization reviews (DURs) would prove valuable in delivering enhanced patient care. Of 
the five measures related to DURs, three were strongly supported (> 80% agreement): the 
need for complete medication profiles, reduced prescribing problems and reduced 
hospital admissions. To a lesser extent (69.6%), community pharmacists believed DUR 
functions would be valued by their clients. Overall, 90.3% of community pharmacists 
agreed DURs would be an important function ofthe Pharmacy Network. 
The availability of a complete medication profile in performing DURs is core to a 
Pharmacy Network. However, if a pharmacist believes that his/her clients are regular 
customers and only have their prescriptions filled at their store, it would be expected that 
the value of the DUR function would diminish. Only 17.2% of pharmacists in this study 
indicated that they felt the Pharmacy Network would not be relevant to their clients as 
most of them are regular customers. This result is similar to the findings of Kozyrskyi, et 
al., (1998) who found 13.5% of pharmacists agreed that the DPIN was not relevant to their 
clients as most were regular customers. It is interesting to note that ofthose pharmacists who 
felt the Pharmacy Network would not be relevant (n = 37), 89.2% still agreed that DURs 
will be an important function of the Pharmacy Network. 
Over 90% of community pharmacists in this present study agreed that DURs 
would reduce prescribing problems. The benefit of DURs in reducing prescribing 
problems is widely accepted. Annstrong & Denemark (1998) investigated 807,017 
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claims that resulted in 83,260 DUR alerts. Almost 21% of these 83,260 prescriptions 
were not dispensed because of the DUR message alerting the pharmacists to a potential 
problem. A study by Armstrong and Markson (1997) found that pharmacists valued DUR 
alerts which identified medication overuse and drug interactions. 
This study found that over 80% of community pharmacists felt DURs, based on 
all prescriptions prescribed, would significantly reduce hospital admissions. 
Hospitalization due to adverse drug reactions is a common occurrence in today's society. 
A study by Moore, et al., (1998) found that 6.6% of hospitalized patients had significant 
ADRs, and that between 5% and 9% of hospital costs were related to ADRs. Green, et al., 
(2000) found that ADRs were responsible for 7.5% of all hospital admissions, and that 
the actual number of ADR admissions may have increased in recent years. 
As expected, there was no significant difference across age groups in the level of 
agreement of community pharmacists in the value ofDURs that access a complete patient 
profile, reduce prescribing problems, or reduce hospital admissions. An incomplete 
medication profile would result in an incomplete DUR, and pharmacists, regardless of 
age, recognized that not having all prescription information for a patient when carrying 
out DURs would limit its value. A significant difference was found between younger and 
older age groups when pharmacists were asked if they felt that their clients would value 
DURs (64.1% versus 76.9%). These percentages are still higher than what was found in 
the post-implementation study by Kozyrskyi, et al., (1998), where only 58.6% of 
pharmacists felt clients value the drug monitoring services they provide through the use of 
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the DPIN. It is most notable that here too, the majority of pharmacists felt that their 
clients would value DUR. 
Although not statistically significant, younger pharmacists in this study tended to 
agree more than their older colleagues that DURs would reduce prescribing problems and 
hospital admissions, and that overall the DUR function would be an important function of 
the Pharmacy Network. Younger pharmacists in this study were introduced to technology 
much earlier in their careers and may more readily except the benefits of technology in 
their profession. Older pharmacists, who have carried out DURs manually for the better 
part of their careers, may not have the same level of confidence in current technology. 
While these results are not conclusive, they are similar to an earlier study by Simpson & 
and Kenrick (1997) which found that younger nurses had more positive computer-related 
attitudes than their older colleagues. 
In comparing the perceived value of DURs across age groups an interesting 
paradox has emerged; younger pharmacists appear to support the value of a DUR 
function more so than their older colleagues, however it is the older pharmacists who feel 
more strongly that their patients will value the services provided through the DUR 
function. Older pharmacists, while not fully accepting electronic DURs, may still feel 
that their clients have a higher comfort level with technology in the pharmacy. 
In comparing the perceived value of a DUR function across gender it was found 
that the females' level of agreement was higher than that of males for all DUR measures, 
although only two were statistically significant: that their clients would value DUR 
services, and that the DUR function would be an important function of the Pharmacy 
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Network. Females in this study were found to be generally younger than male 
pharmacists (34.7 years versus 41.6 years), work in a chain store (71.9% versus 61.7%), 
and work at a pharmacy in an urban community (59.0% versus 47.5%). Given these 
demographic characteristics, it is reasonable to assume that a larger proportion female 
pharmacists in this study worked in pharmacies where large volumes of prescriptions are 
filled, and would rely more on technology in their day-to-day work activities. These 
findings should not lead one to conclude that female pharmacists in this study are more 
supportive of technology in general, or for DUR functions in particular. Although 
research from the 1980s tended to support the hypothesis that males had more positive 
attitudes than females with respect to computer technology (Ray, Sormunen & Harris, 
1999), more recent studies have found gender not to be correlated with computer attitudes 
(Brown & Coney, 1994; Shaw & Gant, 2002). 
In comparing the differences in perceived value of DUR measures across 
education, more pharmacists with a diploma felt their clients would value DUR services. 
A possible reason for this difference in agreement between education levels is that 
pharmacists with a diploma had more years experience (25.0 versus 7.1), than those 
pharmacists with a B.Sc .. It may be that as a pharmacist gains experience, they build up a 
relationship with many of their clients, and as a result of this relationship they are 
comfortable in providing regular DUR services, which are in tum appreciated by the 
client. 
In summary, the perceived value of a DUR function was high among pharmacists 
in this study. Differences in the perceived value of a DUR function were primarily found 
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between age groups, suggesting that a larger proportion of younger pharmacists agree the 
DUR function would be valuable to pharmacists, whereas a larger proportion of older 
pharmacists feel their clients will value the DUR function. 
2) Perceived Value of Computerized Physician Order Entry 
Of the eight Computerized Physician Order Entry (CPOE) measures in this study, 
s1x were strongly supported (> 80% agreement) by community pharmacists. These 
included: removing problems with illegible handwriting, checking dose-ceilings, 
checking allergy information, screening for drug interactions, providing complete patient 
profiles, and providing real time information on dose algorithms. Providing information 
on medication appropriateness (71.5%) and default doses for normal conditions (69.6%) 
received somewhat less support. The CPOE function that received the strongest support 
was removing problems with illegible handwriting (97.2%), which is not surprising. The 
ability of CPOE to remove problems with illegible handwriting and ensure that the 
medication order is complete and unambiguous is widely accepted (Bates, et al., 1999; 
Ferren, 2002; Foster & Antonelli, 2002). 
CPOE has also been shown to enhance patient safety by providing clinical 
guidelines and alerts for default dosages for normal conditions. For example, if a patient 
is prescribed too much, or too strong a dose of a medication than would be normally 
provided to a similar patient, the CPOE would send an alert to the pharmacist. This is of 
particular benefit to pediatric patients, where medication errors occur at similar rates to 
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that of adults but are three times more likely to cause harm (Fortescue, et al., 2003). 
Kaushal, Barker & Bates (2001) concluded that the benefits of CPOE may be even 
greater in the pediatric population given the need for dosages to be weight-based. 
The perceived value of CPOE by community pharmacists in enhancing patient 
safety through the provision of default doses (69.7%) and dose ceilings (73.1%) was 
evident in this study. A majority of community pharmacists in this study also agreed that 
CPOE would enhance patient safety by checking for allergy information (85.1 %) and 
screening for drug interactions (83.7%). Kozyrskyj, et al., (1998) found that 58.6% of 
community pharmacists surveyed agreed the DPIN enhanced their ability to identify drug-
related problems for clients. 
There was no significant difference across age groups or education in community 
pharmacists' level of agreement for any of the eight CPOE measures. With respect to 
gender the only significant difference found was the ability of CPOE to remove problems 
with illegible handwriting. While female pharmacists may be more comfortable in 
utilizing technology to replace paper prescriptions, it should be noted that the value of 
CPOE to remove problems with illegible hand writing was high for both males and 
females (94.4% versus 100.0%). When measures of CPOE were compared across the 
number of years practicing, a statistically significant difference was found between 
community pharmacists with < 12 and 12+ years experience regarding the ability of 
CPOE to check for dosage ceilings (78.1% versus 88.9%). That a larger proportion of 
pharmacists with 12+ years experience valued the function of checking for dose ceilings 
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may be because these pharmacists have more experience with adverse drug reactions 
caused by improper medication dosage. 
Place of business was found to be significant for two measures of CPOE; 
providing a complete patient profile (urban 90.7% versus rural 79.4%) and providing 
information on medication appropriateness (urban 78.0% versus rural 66.7%). 
Differences in the value of CPOE in providing a complete patient profile may be the 
result of pharmacists in urban areas relying more on technology, as they generally fill 
higher volumes of prescriptions than pharmacists working in rural communities. Urban 
areas also provide many options for clients when they wish to have a prescription filled, 
which would result in a dispersed/fragmented medication profile. Clients in rural areas 
would tend to have limited options as there may be only one pharmacy serving the 
community. 
Although there is considerable research identifying the benefits of CPOE, the 
costs for such systems are substantial both in terms of technology and organizational 
restructuring (Kuperman & Gibson, 2003). It will be critical that physicians and 
pharmacists in Newfoundland and Labrador are provided with appropriate training in 
CPOE prior to its implementation if the full benefits of CPOE are to be realized. 
3) Perceived Value ofPost-Market Surveillance (Adverse Drug Reaction Reporting) 
Community pharmacists in this study reported an average of 2.5 ADRs a year, 
with male pharmacists reporting more than 3 times as many ADRs as female pharmacists. 
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Pharmacists 37 years of age and older, had obtained a diploma, and/or were practicing 12 
or more years reported almost 3 times as many ADRs as those under 37 years of age, 
graduated with a B.Sc., and/or were practicing less than 12 years. As previously 
discussed males in this study were generally older than female pharmacists, work as an 
independent, and work in a pharmacy located in a rural community. Given this, a larger 
proportion male pharmacists in this study may work in pharmacies where smaller 
volumes of prescriptions are filled, and subsequently would have more time to complete 
reports on ADRs, which is currently a manual (and time consuming) process. Another 
possible explanation for the higher reporting of ADRs by males in this study is that by 
working in rural communities these pharmacists may have more interaction with their 
clients and from this interaction, become more aware of adverse drug reactions than 
pharmacists working in high volume urban pharmacies. Although pharmacists in rural 
communities were found to report more ADRs than pharmacists in urban communities 
(3 .1 versus 1.9), this difference was not statistically significant. 
In Canada, suspected ADRs are reported to Health Canada, while in the US, 
reports are forwarded to the Food and Drug Administration (FDA). Health Canada 
received a total of 8,566 reports of suspected ADRs from all provinces in 2002. These 
reports were provided mainly by pharmacists, physicians, nurses, dentists and coroners 
(Health Canada, Canadian Adverse Reaction Newsletter, Vol13, No.2: April2003). In a 
post-marketing surveillance study by Roeser & Rohan (1990) it was estimated that 50% 
of all ADR reports are submitted by hospitals and the remaining by physicians, dentists 
and pharmacists. A total 513 ADRs were reported by the 210 community pharmacists 
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responding to this question (7 did not answer this question). However, it is not known if 
pharmacists in this study reported all these 513 ADRs to Health Canada. The question 
asked only the average number of ADRs reported in one year and it is possible that 
community pharmacists in this study also included the reporting of suspected ADRs to 
the prescribing physician or other health professionals in the 513 ADRs reported. 
Although the value of reporting adverse drug reactions in a population is widely 
accepted, the usefulness of available information is limited due to substantial 
underreporting (Heeley, et al., 2001; Hasford, Goettler, Munter & Muller-
Oerlinghausen, 2002; Eland, et al., 1999). It has been estimated that only 10% of ADRs 
are self-reported. The main reasons given by health professionals for not reporting ADRs 
include: uncertainty of causation, the ADR being trivial or too well known, not aware of 
need to report, did not know how to report, or were too busy (Eland, et al., 1999; 
Hansford, et al., 2002). Community pharmacists responding to this survey reported, on 
average, less than 3 adverse drug events a year, although the majority indicated that they 
would report more ADRs if it could be done electronically through the Pharmacy 
Network. It is assumed that the potential for increased reporting through the Pharmacy 
Network is due in large part to the reporting being carried out electronically, rather than 
the current process which is manual, and labour intensive. While pharmacists in this 
study have indicated they would increase reporting through the Pharmacy Network, there 
are still a considerable number (31.3%) who feel their dispensary will be too busy to 
respond to information provided through the Pharmacy Network. 
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The need for the Phannacy Network to be user friendly was a major requirement 
expressed by pharmacists. If the network is difficult to use, it will not free up time, and 
pharmacists will not use it. This concern is evident by 89.3% of community phannacists 
in this study indicating that a comprehensive orientation to the Phannacy Network is 
required prior to its implementation. Extensive pre-implementation training was also 
found to be critical in the study by Kozyrskyj, et al., (1998), where only 42.3% of 
pharmacists felt the implementation phase allowed for sufficient orientation on to how to 
use the DPIN in Manitoba. 
4) Perceived Value ofPrescription Profiling 
In the absence of a Pharmacy Network, the majority of community pharmacists 
(59.9%) ask the patient what medications they are currently receiving. Other methods to 
obtain medication profiles included asking other health professionals (15.5%), asking 
members of the patient's family (12.5%), using the computer profile in that specific store 
(11.5%), and asking the client to bring all current medications into the pharmacy (9.5%). 
It is interesting to note that 11.5% of pharmacists would use still their computer 
profile even if it would only provide those medications dispensed in their own pharmacy. 
Given the hypothesis that rural pharmacists would be more confident than urban 
pharmacists that their clients did not 'pharmacy shop', it would be expected that rural 
pharmacists would rely more on their computer profiles than urban pharmacists. This was 
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in fact the case, with rural pharmacists checking their computer profile almost twice as 
frequently as urban pharmacists (15.7% versus 8.0%). 
In the absence of a Pharmacy Network, 34.6% of community pharmacists in this 
study were still confident that they knew the total number of medications their clients 
were prescribed. The hypothesis that pharmacists operating in smaller communities 
would be more confident in having a complete patient profile, given their patients limited 
choices for filling prescriptions, was not supported by the results. There was no 
measurable difference in pharmacist's level of confidence that they had a complete 
profile of their patient's medications for pharmacists working in either urban (34.8%) or 
rural (35.3%) Newfoundland and Labrador. 
5) Pharmaceutical Care 
Pharmaceutical care can be broadly defined as the responsible provision of drug 
therapy for the purpose of achieving definite outcomes that improves a patient's quality 
of life (Crealey, Sturgess, McElnay & Hughes, 2003). This study, while not specifically 
addressing the role of pharmacists in the delivery of pharmaceutical care, did find strong 
support from community pharmacists for functions proposed for the Newfoundland and 
Labrador Pharmacy Network that would support the delivery of these enhanced services. 
The functions of drug utilization review (90.3%), computerized physician order 
entry (82.2%) and electronic reporting of adverse drug events (87.6%) were strongly 
supported by community pharmacists in this study. While the ability for community 
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pharmacists to access more comprehensive medication information is essential, patient 
care would be greatly enhanced when the pharmacist is made part of the patient's care 
management team. In working with physicians and other health care professionals the 
continuum of patient care is maximized (Hassell, Noyce, Rogers, Harris & Wilkinson, 
1997). 
There is some resistance from the physician community in expanding the role of 
pharmacists in the delivery of patient care. A study by Bailie & Romeo, (1996) found 
that physicians agreed that pharmacists should report adverse drug reactions and advise 
them about cost-effective prescribing, but there was little support for pharmacists 
providing screening services or dispensing antibiotics for minor aliments (such as a sore 
throat) without a prescription. The provision of enhanced pharmaceutical care by 
community pharmacists in Newfoundland and Labrador will be possible when the 
Pharmacy Network is implemented. However communication links between pharmacists 
and physicians will need to be better established if this continuum of patient care is to be 
realized. This study found that only 65.0% of community pharmacists agreed the 
Pharmacy Network would improve their relationship with physicians, suggesting there is 
some hesitation on the part of pharmacists that physicians will accept their expanded role 
in delivering enhanced patient care. In comparison, Kozyrskyi, et al., (1998) found that 
44.1% of pharmacists agreed that the DPIN had improved their relationship with 
physicians, while 28.8% felt physicians were not receptive to pharmacist interventions. 
While the role that community pharmacists in Newfoundland and Labrador will 
play in the patient's care management team has yet to be defined, the majority (94.9%) of 
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community pharmacists in this study agreed the Pharmacy Network would benefit their 
practice. This level of agreement is somewhat higher than found in the Kozyrskyj, et al., 
(1998) study, where 79.3% of pharmacists indicated that their initial expectations were 
that the DPIN would benefit their practice. After working with the DPIN for a period oftime 
this agreement increased slightly to 80.2%. 
As discussed previously, the benefits of the Pharmacy Network to both pharmacists 
and clients will be maximized only if it is easy to use, and frees up time for the pharmacists 
to deliver services other than dispensing medications. In this respect, the expectation of 
pharmacists for the Pharmacy Network is high, with only 8.3% indicating that they felt it 
would interfere with customer service. With such high expectations, it will be critical that 
the Pharmacy Network in Newfoundland and Labrador achieves this goal, given in 
Manitoba, Kozyrskyj, et al., (1998) found 28.8% of pharmacists felt the DPIN has 
interfered with customer service. 
6) Payment for Pharmaceutical Care 
Community pharmacists were asked whether they should be reimbursed for 
specific pharmaceutical services. Providing counseling services (82.9%), monitoring 
patient outcomes (88.9%), identifying medication appropriateness based on a patient's 
medical history (86.6%) and working with physicians to ensure the best possible 
medications are prescribed (89.4%), were all services for which the majority of 
pharmacists agreed they should be compensated. 
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When broken out by gender, it was found that female pharmacists were more 
supportive of payments for pharmaceutical care than their male colleagues. Female 
pharmacists in this study were generally younger and perhaps more comfortable in using 
technology to provide enhanced patient care. However, they expect to be appropriately 
reimbursed for these services. Conversely, male pharmacists were generally older, and 
may feel that these services have always been provided to patients at no cost, and that the 
implementation of a Pharmacy Network would not change the way they have always 
provided client services. 
As a supplement to survey data collected for this study, provincial pharmacy 
associations across Canada were contacted by the researcher and asked if and how 
community pharmacists were compensated for pharmaceutical care services. Of those 
jurisdictions responding, PEl, Ontario, New Brunswick and Newfoundland and Labrador 
appear not to provide payments for any pharmaceutical care services, Nova Scotia, 
Manitoba and Saskatchewan will pay for some services, while British Columbia and 
Quebec have comprehensive payment programs in place for community pharmacists. In 
July 2003, the Ontario government announced a $3-million pilot project to reimburse 
pharmacists for giving patient advice and working closer with doctors. Remuneration for 
community pharmacists has always been tied to the dispensing of medications and it is 
felt this pilot will move pharmacists into the area of pharmaceutical care (Canada.com 
News, July 4, 2003) 
A study by Miller & Ortmeier (1995) of 590 community pharmacies in the US 
found that financial incentives were the most important motivators in providing 
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pharmacy services. If the Newfoundland and Labrador government does not provide 
financial incentives to community pharmacists, it is unlikely that pharmaceutical care 
services will increase to any degree as a result of the Pharmacy Network. In Manitoba, 
Kozyrskyj, et al., (1998) found 74.6% of pharmacists surveyed agreed a potential problem 
was that they were not reimbursed for the services they provide as a result ofDPIN 
An earlier study by Zelnio, Nelson Jr & Beno (1984) found that community 
pharmacists were more likely to provide pharmaceutical services if they held advanced 
degrees, or were involved in continuing education. The study also found that confidence 
in providing pharmaceutical services increased with increased education and/or training. 
This may have implications in this province as it is only since 1990 that a B.Sc. was 
offered in pharmacy at Memorial University, and up to December 2002, only 194 of 
community pharmacists in the province ( 41%) had graduated from this program. 
Consideration must also be given to how busy a pharmacist is when determining 
the level of pharmaceutical care that may be provided. A study by Christensen & Hansen 
(1999) found that the performance of pharmaceutical care was strongly affected by 
practice setting and volume of prescriptions dispensed. In this study only 8.3% of 
community pharmacists felt the additional information provided through the Pharmacy 
Network would interfere with customer service, whereas 31.3% felt their dispensary 
would be too busy to respond to information provided by the Pharmacy Network. 
Community pharmacists, while valuing the information provided through a pharmacy 
network, may not have time to take advantage of the additional information that will be 
available. However, given the appropriate financial incentives, the delivery of 
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pharmaceutical care services may become readily accepted m Newfoundland and 
Labrador's community pharmacies. 
Limitations of the Study 
The limitations of the study included: 
1) A relatively low response rate to the survey (49.9%) which resulted in a 
potentially non-random sample. Due to a lack of demographic information 
available on the population of community pharmacists in the province, the 
investigator was unable to confirm that the sample is representative of all 
community pharmacists in the province; 
2) A Type II error may have been introduced as a result of making multiple 
comparisons. The decision to analyze the survey data using univariate techniques 
limits the conclusions one can draw from the results. A multivariate approach 
would have identified predictors of whether a community pharmacist supports 
various functions of the Pharmacy Network; 
3) While the focus of this study was on community pharmacists perceived value of a 
Pharmacy Network pre-implementation, it is recognized that a fully function 
Pharmacy Network would also include linkages to physician offices and hospital 
pharmacies and emergency rooms. A more comprehensive measure of perceived 
value would need to include these other stakeholder groups; 
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4) As this was a study of the perceived value of a pharmacy network before it is 
implemented, it is possible that the results are biased by socially desirable 
responses; and 
5) The questionnaire was designed by the investigator and was not extensively tested 
for reliability and validity. 
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CHAPTERV 
Summary, Recommendations and Conclusions 
Summary 
Recent advances in technology now provide community pharmacists an 
opportunity to deliver enhanced patient care. With the implementation of the Pharmacy 
Network in Newfoundland and Labrador community pharmacists will be able to carry out 
comprehensive drug utilization reviews (DURs), access a patient's complete medication 
profile, report adverse drug reactions (ADRs) more efficiently, and improve patient 
safety through access to computerized physician order entry (CPOE). 
This study was carried out to: (1) measure the perceived value to community 
pharmacists of specific role enhancements as a result of implementing the Pharmacy 
Network; (2) measure the perceived impact that changes in business practices will have 
on community pharmacists as a result of the Pharmacy Network; and (3) identify key 
functions of the Pharmacy Network, and determine the perceived benefit to community 
pharmacists ofthese functions. 
The setting for the study was all 171 chain and independent community 
pharmacies operating in the province at the time of the study. All 435 community 
pharmacists working in these pharmacies were mailed a survey package, with 219 
responding, 217 ofwhich were included in the quantitative analysis of the fmdings. 
Data was collected through a questionnaire developed by the investigator with 
results presented as descriptive statistics. Demographic information was presented which 
95 
described the sample with respect to age, gender, education and work environment. Using 
a five-point Likert scale, the perceived value of drug utilization reviews, prescription 
profiling, physician order entry and adverse drug reaction reporting were measured. The 
expectations of community pharmacists to deliver and be remunerated for providing 
pharmaceutical services was also measured. 
The findings of this study indicate that community pharmacists strongly support 
the functions proposed for the Newfoundland and Labrador Pharmacy Network. 
Community pharmacists felt DURs would prove valuable in delivering enhanced patient 
care. Access to complete medication profiles in support of DURs would reduce 
prescribing problems and subsequent hospital admissions. To a lesser extent, community 
pharmacists believed DUR functions would be valued by their clients. 
The Pharmacy Network is expected to address the current process of reporting 
ADRs, which at present is very time consuming. There was strong support for the CPOE 
function mainly because it would remove problems with illegible handwriting. Providing 
information on medication appropriateness and default doses for normal conditions 
received somewhat less support. 
Through having access to comprehensive patient drug information, and working 
m partnership with other health care professionals, community pharmacists would 
contribute to improved patient outcomes, while at the same time advancing their role 
from one of only dispensing medications to one where a complete set of pharmaceutical 
services are provided. 
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Realizing this enhanced role of community pharmacists will not be without its 
challenges. Moving from a business model where dispensing medications is the primary 
means for generating revenue, to one where payment (and therefore income) is provided 
for the delivery of pharmaceutical care, will require support from government, other 
health professionals and the general public. 
Implications for Future Research 
This study provided important baseline information about community 
pharmacists' expectations of a pharmacy network pre-implementation, and is the only 
known study of its kind. The sample frame was limited to community pharmacists and 
had only a modest response rate. Consideration should be given to duplicating the study 
in another jurisdiction with a) more intense efforts to achieve a higher response rate; b) 
inclusion of hospital pharmacists and physicians and c) development of a more specific 
measure for ADR reporting. 
In addition, a follow-up post-implementation study should be conducted to 
determine the change in expectations of a pharmacy network once community 
pharmacists have had experience with it. 
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Conclusion 
The results of this original study indicate strong support for and high perceived 
value by community pharmacists for the enhanced care that they would be able to provide 
once the Pharmacy Network is implemented. It is important to duplicate this study in 
other settings to determine if these findings are robust across jurisdictions, and to 
compare these findings with studies conducted post-implementation of a pharmacy 
network. 
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APPENDIX A 
Summary of the Newfoundland and Labrador 
Pharmacy Network Scoping Process 
Functions to be included in the development of the proposed Pharmacy Network 
were identified through the Pharmacy Network Project Scope. The Newfoundland and 
Labrador Centre for Health Information (NLCHI) Pharmacy Network Project Team 
(Project Team) began work in September 2002 and completed its work in February 2003. 
The Project Team developed a list of key deliverables, as well as a list of major 
stakeholders who would need to be engaged in an extensive consultation process. These 
stakeholder consultations were carried out over a 6 month period and involved over 800 
stakeholders across the Province. The format of the consultations were either meetings, 
presentations or workshops and provided an avenue for health care professionals, health 
agencies, community groups and government officials to formulate expectations of the 
Pharmacy Network. Another key objective of the consultations was to identify issues that 
would need to be addressed to make the Pharmacy Network successful. 
In addition to having access to the results of the Pharmacy Network consultation 
process, the researcher reviewed published documents on existing pharmacy networks in 
British Columbia, Alberta and Manitoba. These provinces were selected for review as 
they have established pharmacy networks, recognizing that other provinces are either 
planning, or currently implementing pharmacy networks. Additional information was 
provided to the researcher by the Pharmacy Network Project Team which, as part of the 
Project Scope, also carried out an extensive jurisdictional review. This jurisdictional 
review focused on identifying pharmacy network functions and associated infrastructure, 
identifying risks, and determining successes and failures experienced since 
implementation. As a result of the stakeholder consultations and a review of existing 
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pharmacy networks in other provinces, the Pharmacy Network Project Team have 
proposed that the Pharmacy Network will include several key functions. 
The Pharmacy Network will provide on-line, comprehensive medication profiles 
(Prescription Profiling). Access to complete prescription information will allow 
community pharmacists to provide enhanced quality of care and reduce wastage resulting 
from over utilization and prescribing. The Pharmacy Network will permit physicians to 
submit prescriptions electronically (Computerized Physician Order Entry), which would 
significantly reduce errors resulting from illegible handwriting, provide information in 
real time on allergies and drug cost, as well as provide access to relevant clinical 
guidelines. Drug analysis will be carried out on all active medications in the patients 
profile (Drug Utilization Reviews). Real time prescription analysis will check for 
appropriate drug utilization by monitoring dosage amounts and possible drug interactions 
or duplication. Both the physician and the community pharmacists will be able to record 
an adverse drug reaction (ADR) directly in the patient's prescription profile (Prescription 
Monitoring). The ADR report would then either be sent electronically, or by Fax, to 
Health Canada. The Pharmacy Network will also allow for the identification of the source 
of the ADR (health care provider or patient). 
It has also been proposed that the Pharmacy Network would support on-line real 
time adjudication for claims submitted for clients of the Newfoundland and Labrador 
Prescription Drug Program (NLPDP). The NLPDP is the provincial government drug 
program and provides prescription drug coverage to low-income residents of the 
Province. This function was identified by community pharmacists as critical to the 
success of the Pharmacy Network, however this function was beyond the scope of this 
study. 
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Change Management Issues 
When new systems or processes are introduced into a work environment changes 
in business practices result, and with this change will be the potential for opposition and 
work slowdowns. In the past many information systems introduced in the work place did 
not achieve the expected benefits. This failure to maximize benefits was largely the result 
of resistance to change in business practices, rather than the system itself. Change 
management is a set of processes or strategies that prepare users for the transition to a 
new way doing business, and as a result increase the chances of success. In developing a 
change management strategy the level of acceptance must be determined by each 
stakeholder group that will be impacted by the new system. Strategies are then 
customized for each group to maximize acceptance and understanding of the new system. 
Change management strategies developed for the proposed Pharmacy Network in 
Newfoundland and Labrador, and those currently implemented in British Columbia, 
Alberta and Manitoba were studied. It should be noted that the majority of information 
developed by provinces when developing/implementing large-scale information systems 
is considered proprietary and was not accessible by the researcher. A considerable 
amount of resources are required in developing business plans for provincial pharmacy 
networks, which are then used to secure federal funding in support of system 
implementation. Provinces are therefore reluctant to share this information. In other cases 
detailed business plans were not required and therefor information on change 
management issues were not addressed to any great degree. The researcher was able to 
obtain high level information on change management in other provinces through 
documents found within the public domain. For the proposed Pharmacy Network, 
information was obtained through interviews with both the Project Director and 
Pharmacy Consultant with NLCHI's Pharmacy Project Team. 
109 
Change Management Strategies 
Information on change management strategies for implementing pharmacy 
networks was obtained from British Columbia, Alberta, Manitoba and Newfoundland and 
Labrador. 
British Columbia 
Several working committees were put in place to provide input and advice to the 
project team developing the pharmacy network (PharmaNet). When PharmaNet became 
operational a change management committee and user group were established. The user 
group is made up of major stakeholder groups, including the Health Ministry, 
pharmacists and the BC College of Pharmacy. A user guide was also prepared and 
distributed which provide user-friendly instructions on how to use the various functions 
available through PharmaNet. Financial assistance in the amount of $3,000 was provided 
to each pharmacy to offset the costs associated with technology upgrades required to 
access the pharmacy network. 
Alberta 
The Pharmaceutical Information Network (PIN) was supported from several 
existing committees and working groups. These include the Senior Reference Committee, 
the Health Authorities' CEOs' WellNet Advisory Committee, the Medical Advisory 
Group to the Alberta Wellnet Initiative, the Pharmacy Advisory Group to the Alberta 
Wellnet Initiative, and the provincial Technical Coordinating Group. The Pharmaceutical 
Information Network Task Force/Steering Committee was established for the PIN and 
provides advice and guidance on issues related to piloting and implementation. 
Membership on the committee includes the College of Physicians and Surgeons of 
Alberta, Alberta Medical Association, Alberta College of Pharmacists, Alberta Health 
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and Wellness, and the council of CEOs of the Health Authorities. The Steering 
Committee is also responsible for approving access to information contained in the PIN. 
Reporting to the Steering Committee is the Pharmaceutical Information Network 
Working Group, which provides advice on how the PIN can be developed so that it is 
user-friendly and improves patient care. 
In addition to the various committees and working groups a comprehensive 
implementation 'toolkit' was developed for health care providers. This toolkit provides 
user-friendly instructions on how to use the PIN. In future it is expected that PIN training 
will be offered as part of the curriculum at medical schools. Alberta also provides 
funding to physicians to assist in purchasing computers and relevant software. It is 
planned that this support will soon be made extended to community pharmacists. 
Manitoba 
There were also a number of working groups established in Manitoba during 
implementation of the Drug Program Information Network (DPIN) and had 
representation from a number of stakeholder groups and were involved in the actual 
design of the DPIN. These groups were instrumental in ensuring that the needs of 
stakeholders were incorporated into the design of the DPIN. The support of the Manitoba 
Pharmaceutical Association and the Manitoba Society of Pharmacists was believed to be 
critical in gaining acceptance of the DPIN. In addition to the development of a training 
toolkit, training was provided by practice management specialist, as well as through a 
"play'' function available in the DPIN. This "play'' function allowed pharmacists to 
become familiar with the functions available through the DPIN without affecting the 
actual data. Pharmacies were provided with a maximum of $1,500 to assist in upgrading 
their information systems. 
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Newfoundland and Labrador (Consultation) 
The proposed change management strategy was designed to maximize benefits by 
promoting both usage and acceptance of the Newfoundland and Labrador Pharmacy 
Network (Pharmacy Network). The goal of the change management strategy is to show 
stakeholders the benefits of having user-friendly, timely access to quality information, 
and through this gain overall acceptance of the Pharmacy Network. The strategies were 
developed to address problem areas while at that same time emphasizing areas of success. 
Through the consultation process the Pharmacy Network project team identified a 
number of issues that stakeholders feel will need to be addressed for the Pharmacy 
Network to be successful: 
Computer Skills 
To varying degrees, pharmacists will require training and support before they become 
comfortable using the Pharmacy Network. 
Telecommunications 
Less advanced telecommunication capabilities in remote areas may make access to the 
Pharmacy Network more difficult than in larger populated areas. 
Workload 
The Pharmacy Network must make the work carried out by pharmacists easier. It cannot 
increase the time required to treat a patient. 
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Compensation 
The Pharmacy Network will provide new functions for community pharmacists. These 
functions will require additional effort and pharmacists feel they should be appropriately 
compensated. 
Pharmacists believe they should not be burdened with the costs of implementing new 
software/hardware required to access the Pharmacy Network. 
Privacy and Confidentiality 
Patient privacy must be assured or they may not want their prescription data to be part of 
the Pharmacy Network. Community pharmacists indicated that the time to obtain consent 
from the patient must not interfere with current business practices. 
Change Management Strategies Proposed in Newfoundland and Labrador 
The proposed change management strategies developed by the NLCHI Project Team 
include: 
Government Sponsor 
The sponsor will have the authority to ensure that there is motivation for change. 
Standards of Practice 
The NLCHI Project Team will work closely with relevant regulatory bodies to ensure 
standards of practice are aligned with the Pharmacy Network. 
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Pharmacy Network Champions 
Each site is to have an internal champion to promote the value of the Pharmacy Network. 
Multi-Disciplinary Working Committees 
These Committees will be involved in formulating work processes to support providers in 
using the Pharmacy Network. 
Training 
The training strategy will include: 
Train the trainer 
Combination of web-based, classroom and one-on-one training 
Providing training manuals 
Incorporating continuing education credits 
Training new health care workers coming to the Province 
Development of Communication Tools 
The communication strategy will include: 
Audience specific presentations 
Brochures 
Newsletters 
Public education 
TV and Radio announcements 
Value-Add Information 
The Pharmacy Network would provide an opportunity to provide access to vetted value-
added resources. 
Implementation Toolkit 
The toolkit will provide step-by-step instructions explaining the new processes and 
workflows. 
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Pilot Sites 
Piloting the Pharmacy Network has many advantages such as the opportunity to address 
technical and workflow issues prior to full implementation. 
Help Desk 
The help desk will provide support before and after implementation. 
Evaluation 
The evaluation strategy will include: 
Post-implementation evaluation (survey 6 months post-implementation) 
Clinical evidence ofbenefits shared 
Determining trends in access by sites 
Public Education 
Public acceptance is critical to the success of the Pharmacy Network. The public 
campaign will include media advertising, printed materials and stakeholder involvement. 
Specific Role Enhancements 
The proposed Newfoundland and Labrador Pharmacy Network will provide 
community pharmacists with an opportunity to increase their scope of practice. The 
researcher had the opportunity to attend two consultations sessions held with community 
pharmacists at the Radison Hotel in St. John's. These consultations took the forum of a 
Power Point Presentation with opportunities for pharmacists to provide feedback after 
each function or issue was identified by the Project Team. One question asked of 
pharmacists at the conclusion of the presentation was what did they feel would the 
benefits of the Pharmacy Network. Responses to this question provided insight into 
opportunities for role enhancements perceived by pharmacists as a result of the 
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Pharmacy Network. Additional feedback on consultations that took place outside St. 
John's were provided to the researcher by the Pharmacy Network Project Team. 
Community Pharmacists feel the Pharmacy Network will free up time which is 
currently taken up with dispensing medications. This free time could them be better 
utilized by providing pharmaceutical care to patients. The availability of on-line patient 
information would allow the pharmacist to make safer and easier decisions about a 
patient diagnosis and treatment. Many pharmacists also felt that the Pharmacy Network 
would provide seamless care to the patient through improved coordination of services 
provided by many different health professionals. The provision of these enhanced 
services would not only improve patient care, but would increase public confidence in 
overall pharmacy profession. The ability to be paid for these enhanced services was felt 
to be critical to many community pharmacists. 
A review of published documents from British Columbia, Alberta and Manitoba 
provided minimal information on perceived role enhancements prior to implementing a 
pharmacy network. These provinces were not required to carry out detailed business 
plans prior to implementing pharmacy networks, and because of this, little information 
was available post-implementation. It was found that in British Columbia warnings of 
prescription interactions and duplication resulted in a significant number of prescriptions 
not being filled. In Alberta, pharmacists involved in the pharmacy network pilot felt 
unnecessary phone calls to physicians were reduced, allowing for more efficient use of 
their time. However, pilot community pharmacist located in smaller communities felt 
they did not realize the full benefits of the pharmacy network as their patients generally 
do not have many options on where they can fill their prescriptions. In Manitoba, a post-
implementation survey found 80% of pharmacists agreed the pharmacy network 
benefited their practice. 
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APPENDIX B-1 
November 29, 2002 
Dear Mr. Sir/Madam: 
The Newfoundland and Labrador Centre for Health fuformation (NLCHI) is a 
provincial agency mandated to build a provincial Health fuformation Network (HIN). 
The HIN, when completed, will enable information sharing amongst all providers of 
health care and its services. The first phase, the Unique Personal Identifier/ Client 
Registry, is now operational. Completed at a cost of $3.6M, it provides a comprehensive 
registry of all people accessing health services in the province. The second phase of the 
HIN is the Newfoundland and Labrador Pharmacy Network (NPN). The NPN will 
provide prescription medication information sharing between community and 
institutional pharmacies, physician offices, emergency rooms, other health professionals, 
and the Newfoundland and Labrador Prescription Drug Program (NLPDP). 
This study, by Mr. MacDonald, to determine the perceived value of the NPN prior 
to implementation, will assist NLCHI in determining the true value of introducing the 
integrated network. I support Mr. MacDonald's study and would ask that you assist him 
by completing the enclosed questionnaire. 
Sincerely, 
Steve O'Reilly 
CEO 
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APPENDIX B-2 
December 10, 2002 
Dear Sir/Madam: 
The Newfoundland and Labrador Centre for Health Information (NLCHI) is 
currently carrying out a scoping exercise, on behalf of the Government of Newfoundland 
and Labrador, to determine the feasibility of implementing a Provincial Pharmacy 
Network. This initiative presents a unique opportunity to determine the perceived value 
to community pharmacists of the Newfoundland and Labrador Pharmacy Network (NPN) 
prior to its implementation. As part of my Masters' Thesis this survey will investigate the 
perceptions among community pharmacists on issues such as the value of a complete 
patient profile, the usefulness of drug utilization reviews and electronic physician 
prescribing, and the issue of payment for professional (cognitive) services. 
Enclosed in this package is a survey questionnaire, as well as a self-addressed 
return envelope for the return of the completed questionnaire. The study is anonymous, 
no personal identifiable information will be collected as a result of this survey. 
I would like to thank you in advance for participating in this study. 
Sincerely, 
Don MacDonald 
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APPENDIXC 
Thank you for agreeing to complete this questionnaire. As noted in the cover letter, the 
purpose of this study is to get a picture of what pharmacists expect of a Pharmacy 
Network in Newfoundland and Labrador, prior to its implementation. In this province it 
is proposed that the Pharmacy Network will link all hospitals, physician offices and 
community pharmacies and support: 1) computerized physician order entry, 2) 
prescription monitoring, 3) prescription profiling and ( 4) drug utilization reviews. Your 
response is anonymous, no personal identifiers will be attached to this questionnaire. 
Section 1: Demographic 
Note: If you happen to work in more than one Pharmacy, please respond from the 
perspective of the site where most of your time is spent. 
1. Which of the following best describes your current position in the pharmacy 
where you received this questionnaire? (Circle 1 response only) 
a) Manager/Owner/Franchisee 
b) Staff Pharmacist 
c) ReliefPharmacist 
d) Other (Please Specify ) 
45.6% 
48.8% 
5.5% 
0.0% 
2. Is the Pharmacy in which you generally work: 
Part of a Chain 
or 
An Independent 
66.2% 
33.8% 
3. Is this pharmacy located in: 
38.8% a city 
13.6% a community population> 10,000, but not a city 
47.7% a community< 10,000 
4. Do you normally work in more than one Pharmacy in any given week? 
12.9% Yes 
87.1% No 
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5. How many hours per week do you normally work in this pharmacy? 
Mean 37.9 Hours 
6. How many Pharmacists normally work at this Pharmacy? 
7. 
1 (12.5%) 2 (32.9%) 3 (41.2%) 4 or more (13.4%) 
Are you: a) Female 
b) Male 
55.6% 
44.4% 
8. In what year were you born? 
19 
--
Mean = 38.5 years 
9. In what year were you first licensed to practice pharmacy in Canada? 
19 or 20 
---
Mean = 14.8 years 
10. What is your level of training? (Circle all that apply) 
a) B.Sc.(Pharmacy) 57.9% 
b) Ph. C. 40.7% 
c) M.Sc 0.5% 
d) M.B.A. 0.0% 
e) Ph.D. 0.5% 
f) PharmD 0.5% 
g) Other (please specify 0.0% 
11. Please indicate the number of years of experience that you have had as a licensed 
pharmacist in the following pharmacy settings. (Include experience in Canada and 
elsewhere if applicable) 
Number of years at this pharmacy 
Number of years elsewhere in community pharmacy 
Number of years in hospital pharmacy 
Number of years in other areas of practice 
(Please specify) Teaching and Sales 
(Please specify)-------------
Mean 7.1 years 
Mean 7.1 years 
Mean 0.5 years 
Mean 0.3 years 
Mean 0.0 years 
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Section II: Pharmacy Network Functions 
Respond to statement 12 by circling one of the following responses: 
1 Strongly Agree (A) 
2 Somewhat Agree 
3 Neither Agree Nor Disagree 
4 Somewhat Disagree 
5. Strongly Disagree (D) 
Computerized Physician Order Entry 
Several studies have indicated that there are major problems with the order entry stage of 
prescribing medications. Computerized physician order entry is one strategy that has gain 
wide acceptance towards improving this process. 
12. Do you feel that Computerized Physician Order Entry will result in enhanced 
patient safety by: 
(A) 
a) Providing default doses for normal conditions 1 2 
(D) 
3 4 5 
19.2%50.5%22.9%5.1%2.3% 
b) Removing problems with illegible handwriting 1 2 3 4 5 
82.8% 14.4% 1.4% 1.4% 0.0% 
c) Checking dose-ceilings 1 2 3 4 5 
28.0%55.1% 13.6% 2.3%0.9% 
d) Checking allergy information 1 2 3 4 5 
33.0%52.1% 9.8% 5.1%0.0% 
e) Screening for drug interactions 1 2 3 4 5 
39.3%44.4% 10.7% 5.1%0.5% 
f) Providing complete patient profile 1 2 3 4 5 
g) Providing real-time information on dose 
algorithms 
h) Providing information on medication 
appropriateness 
53.1%31.9% 10.8% 3.8%0.5% 
1 2 3 4 5 
34.7% 47.9% 15.0% 1.9%0.5% 
1 2 3 4 5 
26.2%45.3% 22.9% 5.1%0.5% 
121 
Prescription Profiles 
Medication information on a prescription profile may include the type of medication, date 
of prescribing and dispensing, refill dates, quantity, strength and specific directions for 
administering the drug. As well as providing a pharmacist with a list of current 
medications, most prescription profiles provide a 6-12 month prescribing history. 
13. On average, when you need to determine which medications a 
patient is receiving, what percent of time do you: 
a) ask the patient 
b) ask the family of the patient 
c) have the patient bring in all medications to pharmacy 
d) ask other health care providers 
e) other (Please Specify - Check Computer Profile 
14. Are you confident that you know the total number of medications 
your patients are prescribed? 
34.6% Yes 
65.4% No 
Prescription Monitoring 
59.9% 
12.5% 
9.5% 
15.5% 
11.5% 
Adverse drug reactions (ADRs) result in a significant number ofhospital admissions and 
deaths. Prescription monitoring is a system of responding to adverse events in a 
population due to prescription medications. 
15. What is the average number of adverse drug reactions that you report in one year? 
Mean 2.45 
16. Would you be more likely to report an adverse drug reaction electronically? 
88.8% Yes 
11.2% No 
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Respond to statement 17 through 28 by circling one of the following responses: 
1 Strongly Agree (A) 
2 Somewhat Agree 
3 Neither Agree Nor Disagree 
4 Somewhat Disagree 
5. Strongly Disagree (D) 
Drug Utilization Reviews 
Generally Drug Utilization Review alerts identifY the possibility of therapeutic 
duplication, drug interactions, low/high dose, drug over-use/under-use and drug-
pregnancy conflicts. 
17. 
18. 
Drug Utilization Reviews have limited value unless 
carried out on the complete patient profile 
(A) 
1 2 3 
(D) 
4 5 
61.8%27.6% 6.0%3.7%0.9% 
Drug Utilization Reviews based on all prescriptions 
Prescribed will significantly reduce prescribing problems 
( eg. drug interactions, drug duplication) 1 2 3 4 5 
54.4% 36.9% 6.5% 2.3% 0.0% 
19. Drug Utilization Reviews will be an important function 
of the Pharmacy Network 1 2 3 4 5 
52.5% 37.8% 7.4% 0.9% 1.4% 
20 Drug Utilization Reviews based on all prescriptions 
prescribes will significantly reduce hospital admissions 1 2 3 4 5 
37.8%42.4% 17.1%2.3%0.5% 
21. Clients will value the Drug Utilization Reviews services 
that I will provide through my use of Pharmacy Network 
Section III: Cognitive Services 
22. Pharmacists should be reimbursed for the following 
professional (cognitive) services: 
a) Providing Counseling 
1 2 3 4 5 
26.3%43.3%24 .. 0%6.0%0.5% 
A) 
1 2 3 
(D) 
4 5 
60.6%22.2% 10.6% 1.9%4.6% 
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b) Monitoring Outcomes 
c) Identifying medication appropriateness 
Based on a patients medical history 
d) Working with Physicians to ensure the best 
possible medications are prescribed 
Section IV: General 
23. 
24. 
25. 
26. 
27. 
28. 
A comprehensive orientation process will be 
required prior to the implementation phase of 
Pharmacy Network 
I expect the Pharmacy Network would benefit 
my practice as a pharmacist. 
The dispensary is too busy for me to respond to 
information provided by the Pharmacy Network. 
The Pharmacy Network will not be relevant to 
my clients as most of them are regular customers 
The Pharmacy Network will improve my 
Relationship with physicians 
The Pharmacy Network will interfere with customer 
1 2 3 4 5 
67.6%21.3% 7.9%0.9%2.3% 
1 2 3 4 5 
57.4%29.2% 8.3% 2.8% 2.3% 
1 2 3 4 5 
62.0%27.3% 7.4% 1.9% 1.4% 
(A) (D) 
1 2 3 4 5 
62.0% 27.3% 7.4% 1.9% 1.4% 
1 2 3 4 5 
65.9% 27.2% 5.5% 0.9%0.5% 
1 2 3 4 5 
2.3% 29.0% 25.3% 29.0% 14.3% 
1 2 3 4 5 
1.9% 15.3%25.5%34.9% 18.1% 
1 2 3 4 5 
19.4%45.6% 27.6% 6.5% 0.9% 
Service 1 2 3 4 5 
1.4% 6.9% 31.0%35.6%25.0% 
29. Do you currently use a computer in your Pharmacy 
99.1% Yes 
0.9% No 
30. Are there any other comments that you would like to make about your 
expectations of a Pharmacy Network, and how the Pharmacy Network would 
impact upon you or your pharmacy? If so, please use this space and/or the back 
cover for that purpose. 
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Thank you again. Please use the pre-addressed return envelope to return the completed 
questionnaire. Copies of the final report will be available from the investigator, Mr. Don 
MacDonald (709-757-2408, DonM@NLCHI.nfca), or by accessing NLCHI's website at 
www .nlchi.nfca 
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